

1 THE STATE of OHIO,

: SS:

2 COUNTY of CUYAHOGA.

3 -----

4 IN THE COURT OF COMMON PLEAS

5 -----

6 ESTATE OF LAWRENCE BROWN, :
7 plaintiff, :

8 vs.

: Case No. 346342

9 UNIVERSITY HOSPITALS OF
CLEVELAND, et al.,
10 defendants.

11 -----

12 Deposition of GEOFFREY MENDELSON, M.D.,

13 a witness herein, called by the plaintiff for the
14 purpose of cross-examination pursuant to the Ohio Rules
15 of Civil Procedure, taken before Constance Campbell, a
16 Notary Public within and for the State of Ohio, at Mount
17 Sinai Medical Center, One Mount Sinai Drive, Cleveland,
18 Ohio, on TUESDAY, SEPTEMBER 28TH, 1999, commencing at
19 3:00 p.m. pursuant to subpoena.
20
21
22
23
24
25

1 APPEARANCES:

2
3 ON BEHALF OF THE PLAINTIFF:

4 Donna Taylor-Kolis, Esq.
5 Donna Taylor-Kolis Co., LPA
6 330 Standard Building
7 Cleveland, Ohio 44113
8 (216) 861-4300.

9 -----

10
11
12
13
14 ON BEHALF OF THE DEFENDANT ERIN FUREY, M.D.:

15
16 Marc W. Groedel, Esq.
17 Reminger & Reminger
18 The 113 Saint Clair Building
19 Cleveland, Ohio 44114
20 (216) 687-1311.

21 -----

I N D E X

WITNESS:GEOFFREY MENDELSON, M.D.PAGE

Cross-examination by Miss Kolis

5

PLAINTIFF'S EXHIBITSMARKED

A - 1-14-99 preliminary report 12

(FOR COMPLETE INDEX, SEE APPENDIX)

(IF ASCII DISK ORDERED, SEE BACK COVER)

GEOFFREY MENDELSON, M.D.

Geoffrey Mendelson M.D. SIDE OF PAGE

the same is true and accurate. SEE ALSO REVERSE

I have read the foregoing transcript and

The slides show no evidence of an acute embolus, the pathologist doing the autopsy found no evidence of acute embolus. with the knowledge that no acute fresh embolus, no second embolus and the fact that no acute embolus was seen grossly, and no acute embolus is seen microscopically. loose term. recanalization -Census at the hospital is a little lower. We don't ask for..... He has..... developed.....arterial hypertension. The blood... .. poorly oxygenated because he is emphysematous. Blood flow is impaired due to heart failure.. 36/13

PAGE/LINE 19/6-10

1

GEOFFREY MENDELSON, M.D.

2 of lawful age, a witness herein, called by the plaintiff
3 for the purpose of cross-examination pursuant to the
4 Ohio Rules of Civil Procedure, being first duly sworn,
5 as hereinafter certified, was examined and testified as
6 follows:

7

8

MISS KOLIS: Dr. Mendelsohn, I'm
9 pronouncing your name correctly?

10

THE WITNESS: Uh-hum.

11

MISS KOLIS: That's usually the
12 part ■ really mess up on. As you know my name is Donna
13 Kolis, I've been retained to represent the Estate of
14 Lawrence Brown. It has been indicated to me that you
15 have been retained to be an expert witness on behalf of
16 Dr. Erin Furey; is that a correct statement?

17

THE WITNESS: Yes.

18

MISS KOLIS: My purpose today is
19 hopefully to be concise, if that is ever humanly
20 possible, to ask you what opinions you hold, what facts
21 you know, what testimony ■ might expect at trial.

22

I gather of course based on some
23 research I've done, you've given some depositions in the
24 past.

25

THE WITNESS: Correct.

1 MISS KOLIS: I'll remind you of
2 the ground rules of a deposition. You of course I would
3 suspect remember that you have to answer all the
4 questions verbally.

5 THE WITNESS: I do.

6 MISS KOLIS: I at any time I ask
7 a question that you do not understand, which is always
8 highly probable since you're a pathologist, I'm an
9 attorney, you may indicate to me you do not understand
10 my question, we will try to clarify what information I'm
11 seeking; is that acceptable to you?

12 THE WITNESS: Yes is.

13 MISS KOLIS: Although Mr. Groedel
14 isn't quote, unquote your attorney, he is the attorney
15 representing Dr. Furey, accordingly if at any time
16 during the questioning you wish to confer with him, you
17 simply state that for the record, I'll honor that
18 request, that's always acceptable to us.

19 THE WITNESS: okay.

20 -----

21 CROSS-EXAMINATION

22 BY MISS KOLIS:

23 Q. In conjunction with today's deposition I had
24 issued a subpoena, that subpoena requested that you
25 bring with you your original chart regarding this

1 patient. sitting in front of me is a rather large
2 stack, can I interpret that's your chart?

3 A. Yes.

4 Q. May I momentarily look at what ~~is~~ contained in it?

5 A. Sure.

6 Q. Doctor, prior to coming into this room did you
7 remove any documents whatsoever from this chart?

8 A. I removed a copy of my report that is in there
9 that was just another copy and I removed a bill which I
10 sent to Mr. Groedel.

11 Q. No time like the present to ask the question:
12 What is your hourly fee for participating in
13 medical/legal evaluations?

14 A. At this point it's \$275 an hour.

15 Q. That's the amount of money that you will be
16 charging me for your deposition time today?

17 A. Yes,

18 Q. Mr. Groedel and I did not make prior arrangements
19 for the same, at the conclusion of the deposition if you
20 would submit a bill to him he can forward it to me, it
21 will be paid promptly; that's acceptable to you?

22 A. That's okay.

23 Q. I want to go through and name the things in your
24 file to make sure I have them correctly.

25 A letter dated September 2, 1999

1 indicating today's date for the deposition; is that
2 correct?

3 A. okay.

4 Q. A letter which apparently was dated August 27,
5 1999 forwarding to your attention Dr. Wecht's
6 deposition, correct?

7 A. Correct.

8 Q. Then Dr. Wecht's deposition dated July 16, 1999,
9 did you have an opportunity to read Dr. Wecht's
10 deposition prior to today?

11 A. I received it a while back.

12 Q. Have you read it?

13 A. I have.

14 Q. June 15, 1999 correspondence from Mr. Groedel to
15 yourself, it reads: Following our recent discussion I'm
16 enclosing a copy of a report from the plaintiff's
17 pathology expert, Dr. Wecht, as well as the records
18 covering Mr. Brown's hospital stay in issue. Please
19 give me a call after you've had an opportunity to look
20 at this.

21 I gather June 15th was the first time
22 that you had seen the hospital record in this matter?

23 A. I don't recall exactly to be quite honest.

24 Q. In any event, at the minimum on June 15th your own
25 personal copy of the record was supplied to you?

1 A. That's correct.

2 Q. You also received Dr. wecht's preliminary opinion
3 report?

4 A. Whatever the report is, this is the one I
5 received.

6 Q. April 15, 1999?

7 A. Correct.

8 Q. You received -- these are the hospital records,
9 correct?

10 A. Correct.

11 Q. You also received a deposition that would appear
12 to me to be of Dr. Van DePol; do you recall that?

13 A. Correct.

14 Q. Did you know Dr. Van DePol?

15 A. No.

16 Q. Have you had an opportunity to read his
17 deposition?

18 A. Parts of it, yes.

19 Q. Just a note from Mr. Groedel March 9, 1999
20 indicating your deposition for March 15th was cancelled;
21 am I stating that accurately?

22 A. Sure.

23 Q. Another letter from Mr. Groedel discussing the
24 necessity for some trial testimony; is that right?

25 A. Correct.

1 Q. Copy apparently of your preliminary report dated
2 January 14, 1999 to Mr. Groedel?

3 A. Correct.

4 Q. Another letter talking to you about potential
5 trial testimony date of January 28th?

6 A. Okay.

7 Q. And a letter dated January 13, 1999 indicating
8 enclosed please find for your review pathology slides
9 relative to the above-captioned matter from Mr. Groedel,
10 correct?

11 A. Correct.

12 Q. Now that we worked our way completely backward,
13 when did you believe you were first contacted
14 potentially to be an expert witness in this matter?

15 A. Well, I don't recall exactly but since I did get a
16 letter from Mr. Groedel dated January 13, 1999, it would
17 have to be my understanding that I was contacted
18 somewhere around that time.

19 Q. That letter indicates that what he enclosed in his
20 preliminary submission to you was the slides and slides
21 only; would you agree with that?

22 A. Yes.

23 Q. Did you have a telephone conversation with
24 Mr. Groedel prior to the time that he sent you these
25 slides?

1 A. I have no recollection, ■ don't recall whether he
2 called me first and said I'm sending you some slides to
3 look at or --

4 Q. Just sent you a letter?

5 A. usually that is what will happen. I've got some
6 slides I would like you to look at, could you look at
7 them. Then I get the slides, but I don't recall
8 specifically.

9 Q. As of January 13, 1999, did you have enough of a
10 relationship with Mr. Groedel he simply could have
11 authored a letter, sent you slides without first
12 contacting you?

13 A. Every now and then ■ will get some slides sent to
14 me, just enclosed are some slides for your review, that
15 is not what I'm used to though, generally I get the
16 courtesy of a phone call first, are you here, are you in
17 town, do you have the time to look at some slides, yes,
18 I do, then I get the slides.

19 Q. Just wanted to ask.

20 So those were delivered to you on the
21 13th or at least the letter is dated the 13th, by
22 January 14th, the following day, you issued a
23 preliminary letter; are you in agreement with that as
24 the sequence of events?

25 A. My letter is dated the 14th, yes.

1 Q. At the time you received the letter and slides
2 what did you understand your purpose was in having
3 received the slides?

4 A. Well, whenever I receive slides, being a
5 pathologist I don't think one has to be a rocket
6 scientist to figure out someone wants you to look at the
7 slides, give an opinion based on what is present on
8 those slides.

9 I don't recall what discussion went on
10 around that time at all. I received the slides with a
11 letter dated the 13th via Bonnie speed Delivery, they
12 were couriered over here, that would have ordinarily
13 been preceded by a phone call. Then I looked at the
14 slides, issued my report.

15 Q. What I guess I was getting at, were you aware that
16 there was a pending piece of medical malpractice
17 litigation at the time you received the slides?

18 A. Well, since Mr. Groedel ~~was~~ an attorney, ~~was~~ not a
19 surgeon sending me slides diagnostically on a patient,
20 yes. I would understand that there is some question
21 there, that is some question concerning medical
22 malpractice or the potential thereof. I'm being asked
23 to look at the slides and describe or report on what I
24 see.

25 Q. Since this is the entirety of your file, I know

1 I'm asking you to do some things from recollection, do
2 you know as we sit here today whether or not prior to
3 the time you wrote the report on January 14th, as to
4 whether or not you were aware of what the issues in the
5 case were?

6 A. I don't recall how much information was given me
7 previously. ordinarily I do not write a report without
8 at least asking whoever sent me the slides why they are
9 being sent. I do not recall what discussions went on.
10 I only received six slides with an autopsy number which
11 I recognized clearly, which any pathologist would
12 recognize did not represent an entire autopsy. The
13 slides I received were lung, pulmonary artery and
14 another little artery that I assumed was coronary artery
15 given that my report describes my findings on those six
16 lines.

17 MISS KOLIS: what I would like to
18 do is I have a copy of the report which I'm going to let
19 the court reporter mark Plaintiff's Exhibit A.

20 -----
21 (Plaintiff's Exhibit A marked for identification.)

22 -----
23 Q. Doctor, is it fair to state that your report does
24 not contain any opinion testimony as to whether or not
25 there were deviations of accept standard of medical care

1 in this particular case?

2 A. Sorry. ■ didn't get that.

3 MISS KOLIS: Read it back,
4 please.

5 MR. GROEDEL: Dr. Mendelsohn will
6 not be offering opinions as to standard of care issues
7 in the case if that helps you.

8 MISS KOLIS: It does but ■ would
9 like him to answer it on the record. Read it back.

10 -----

11 (Question read.)

12 -----

13 A. Yes, that is correct.

14 Q. That having been said, I recently as in yesterday
15 ■ believe received a courteous message from Mr. Groedel
16 subsequent to the time that you wrote the original
17 report you have now reviewed Dr. wecht's deposition and
18 UH records?

19 A. Correct.

20 Q. Based upon that review you have some additional
21 opinions in this matter; would that be a fair statement?

22 A. Correct.

23 Q. You haven't had the opportunity to actually submit
24 those opinions in writing, correct?

25 A. Correct.

1 Q. We'll get to that in a second.

2 Let's go over briefly, maybe not
3 briefly, the information that is contained in your
4 preliminary report. You indicate that you were able to
5 examine six slides that were submitted to you from
6 University Hospitals of Cleveland; is that correct?

7 A. Correct.

8 Q. The quality of the slides, may I inquire based on
9 your memory were they sufficient for you to make a
10 pathological interpretation of each slide?

11 A. Yes.

12 Q. Quality, size, integrity?

13 A. As good as University Hospitals can do, yes, they
14 were fine.

15 Q. I would like to go through your findings with you
16 I guess line by line if that is all right?

17 A. okay.

18 Q. The first line as I read it into the record, third
19 paragraph, "The lungs are congested and slightly
20 emphysematous with subpleural emphysematous bullae and
21 fibrinous pleuritis.'" what does that mean in terms of
22 findings that may relate to the cause of death, if
23 anything?

24 A. well, the lungs are congested is indicative of
25 some heart failure. Emphysema is a chronic condition of

1 the lungs characterized by expansion of the air spaces.
2 So the lungs were emphysematous, there were subpleural
3 bullae which are large air filled spaces, the fibrinous
4 pleuritis indicates some inflammatory reaction in the
5 lining of the lungs.

6 Q. The next line you state, "The sections of
7 pulmonary artery contain a large, organizing
8 thromboembolus attached to the wall of the artery."

9 Have I read that into the record
10 correctly?

11 A. Correct.

12 Q. You are using the word "sections," did you reach
13 the conclusion contained in this sentence by looking at
14 more than one slide?

15 A. Six slides.

16 Q. This particular finding relates to the overall
17 interpretation you gained from looking at the six
18 slides, correct?

19 A. Yes. I forget how many of the slides included
20 pulmonary artery, but my recollection is there were one
21 or two. I don't recall specifically.

22 Q. You indicate that there was large organizing
23 thromboembolus, in layman's terms, if you have an
24 opinion, based upon looking at the slides alone, with no
25 clinical information, were you able at that time to

1 determine the length of time which the large organizing
2 thromboembolus had been in the pulmonary artery?

3 A. Yes.

4 Q. How could you make that determination?

5 A. Well, I think that follows in the next couple of
6 sentences, there were a whole host of features which
7 I've enumerated which point to this blood clot in the
8 pulmonary artery being at least two weeks old.

9 Q. Why don't you go through for me the whole host of
10 features that led you to conclude that this embolus was
11 at least two weeks old.

12 A. There is early recannulization of the thrombus.
13 There is fibrosis within the thrombus. There is some
14 focal hemosiderin pigment deposition within the
15 thrombus, chronic inflammatory cells within the
16 thrombus, in association with organization, as well as
17 within the wall of the pulmonary artery; so there are
18 chronic inflammatory cells in the wall of the pulmonary
19 artery extending out to the soft tissue around the
20 pulmonary artery.

21 The blood clot in the pulmonary artery
22 is firmly attached to and is being incorporated into the
23 wall of the pulmonary artery. Those features taken
24 together indicate that this pulmonary embolus or blood
25 clot has been there for somewhere around two weeks of

1 age or even longer.

2 Q. As you know, attorneys like to ■ should say on the
3 report we pick at nits because we are afraid we don't
4 know what you mean.

5 In the initial report were you
6 indicating at the minimum the embolus was two weeks old?

7 A. Yes, I think one has to understand here that there
8 ■ no clock in the human body. We always wish there
9 were, ■ know you guys also wish there were, so when ■
10 say two weeks, I'm talking about one week, two weeks.
11 If someone said 12 days or 10 days, ■ have 14 days, I'm
12 prepared to say that is fine. ■ wish changes in the
13 human body were much more precise.

14 Yes, in my opinion, this blood clot has
15 been there for at least two weeks. If you want to
16 rephrase as you did two weeks, or maybe even longer.

17 Q. The letter which ■ received yesterday from
18 Mr. Groedel, ■ assume you haven't seen a copy of it,
19 this ■ the letter I received, Marc will tell you that
20 is his signature I bet.

21 A. okay.

22 Q. You didn't author this letter, Mr. Groedel did, ■
23 would like to ask you a question or two about it.

24 Mr. Groedel indicates to me that,
25 paraphrasing, after your review of Dr. Wecht's

1 deposition and the UH records, based upon the slides and
2 those materials Dr. Mendelsohn has the opinion that
3 the clot found in Mr. Brown's lung at the time of
4 autopsy had been present for at least a number of days.

5 Is your testimony going to be now that
6 it may have been less than two weeks, have you changed
7 your opinion?

8 A. No. My opinion and when I say two weeks, it could
9 be somewhere between 10 and 14 days or 12 and 14,
10 somewhere in that range, sure. For me that is two
11 weeks, talking medically.

12 No, my testimony is that based upon the
13 features that I just went through, that this blood clot
14 has been there for a couple of weeks, or longer.

15 Q. So semantically when I read at least a number of
16 days, that didn't reduce the amount of time, you are
17 still at 10 days or older in terms of the clot found in
18 the lung, correct?

19 A. Yes.

20 Q. Furthermore, it will be Dr. Mendelsohn's opinion
21 that the insertion of a vena cava filter following
22 Dr. Furey's involvement in this case would not have
23 prevented Mr. Brown's demise.

24 Did you indicate to Mr. Groedel orally
25 you would be giving that testimony?

1 A. I forget exactly what I had said. Yes, after ■
2 read Dr. wecht's deposition in which he stated that the
3 patient's death had been caused by an acute
4 thromboembolus, there is no evidence of an acute embolus
5 at the time of autopsy. The slides show no evidence of
6 an acute embolus, the pathologist doing the autopsy
7 found evidence of acute embolus with the knowledge that
8 no acute fresh embolus, no second embolus, the fact that
9 no acute embolus was seen grossly.

10 The fact that no acute embolus is seen
11 microscopically, it is my opinion that there was no
12 second embolus from presumably the lower extremities to
13 have caused Mr. Brown's demise.

14 Q. Let me ask you, I'm going to ask a lot of
15 questions I'm afraid today, that is what we do, have you
16 been asked to testify at trial?

17 A. In this case?

18 Q. um-hum.

19 A. Yes.

20 Q. So it is your intention to offer the testimony
21 that we're discussing today at trial, correct?

22 A. Yes.

23 Q. Your original report then, the information that I
24 received from Mr. Groedel indicates that the additional
25 opinions that you have reached are based upon

1 Dr. Wecht's deposition and UH records.

2 My question is this: Did you factor in
3 Dr. Van DePol's testimony in arriving at your
4 conclusions?

5 A. Yes.

6 Q. You did read that deposition?

7 A. Yes.

8 Q. Did you read his complete autopsy since the time
9 of writing that first report?

10 A. Yes.

11 Q. I wanted make sure I know everything you are
12 relying upon.

13 Have you been made or has the deposition
14 testimony of Dr. Furey been made available to you?

15 A. It's not here, it has not been made available.

16 Q. Dr. Lee?

17 A. No.

18 Q. Dr. Gluck?

19 A. No.

20 Q. Dr. Downs?

21 A. No.

22 Q. I'm going to move to a little different arena.

23 Doctor, this is not the first time that
24 you have appeared as an expert in a medical malpractice
25 case, fair statement?

1 A. Fair statement.

2 Q. Since June of 1997 through the present can you
3 please tell me who your malpractice insurance carriers
4 have been?

5 MR. GROEDEL: objection. You can
6 answer.

7 A. Well, at one time it was PIE Mutual, it was then
8 Mutual Assurance I believe, there may have been a period
9 where it was someone else because we actually -- I don't
10 know if it is the right term, sold our practice, we're
11 now part of a large group practice, they provide medical
12 malpractice. I believe at this point in time it's saint
13 Paul. I don't know. I don't know if there was
14 something in between Mutual Assurance and Saint Paul.
15 I've gotten out of the practice management side of our
16 practice.

17 Q. Mercifully?

18 A. Mercifully. I rely on others to do that for me.
19 PIE, Mutual Assurance, and Saint Paul.

20 Q. could I prevail upon you, it's important as an
21 evidentiary point for myself to confirm through
22 Mr. Groedel by some written document that would support
23 the same during what period of time you were insured by
24 Mutual Assurance?

25 A. It would have been -- I can get that for you. I

1 think it would have been January.

2 MR. GROEDEL: I don't want you to
3 guess. If you don't know, don't speculate.

4 A. Let me get that for you. We were insured by
5 Mutual Assurance for a brief period of time.

6 Q. Have you testified for Mr. Groedel before?

7 A. Yes.

8 Q. How many occasions?

9 A. I think it's -- this may be the fourth case that
10 I've looked at for him. I honestly don't keep count, I
11 think it is the fourth case.

12 Q. Have you testified for other members of his law
13 firm?

14 A. Again, I don't always keep track of attorney's
15 names and which law firms they are with. Yes, I have.
16 I have looked at a case for a Mr. Walters or Walter, I
17 don't believe I ever issued a report in that case.

18 Q. Have you been asked prior to today to evaluate
19 pathology in any medical negligence case that dealt with
20 pulmonary embolus?

21 A. Yes.

22 Q. Can you specifically recall who the attorney was
23 and what the facts or general facts of the case were?

24 A. No.

25 Q. You have no memory of it?

1 A. I honestly have enough facts at my age to remember
2 with diminishing ability to do so, remembering specific
3 patient names and physician names just simply isn't part
4 of that.

5 Q. Back in I'm going to do general time frames, I
6 would say late '80s through the early '90s you provided
7 medical/legal assistance to the law firm of Jacobson,
8 Maynard; would you say that is a fair statement?

9 A. Yes.

10 Q. In reviewing your CV, it seems to me that your
11 area of interest in pathology happens to be in cancers;
12 do you think that is a fair statement about what is on
13 your CV?

14 A. It's one of my areas of interest. I've got many
15
16
17 primary area of interest and experience in pathology is
18 in cancer; would you agree with that?

19 A. It is in cancer, breast cancer, I've written a
20 book on endocrine diseases, my areas of interest are
21 fairly wide.

22 Q. Tell me what your position is here at the
23 hospital.

24 A. I am director, Medical Director of the Department
25 of Pathology. Since I believe it is May or maybe April

1 I have been chief of staff.

2 Q. For the hospital?

3 A. For the hospital.

4 Q. Was that coincident or coinciding with the
5 hospital's filing for reorganization?

6 A. Yes.

7 Q. As the director of the Department of Pathology
8 first of all, how long did you hold that position, when
9 to when?

10 A. I've had that position since 1988.

11 Q. Do you perform autopsies at the hospital?

12 A. We do.

13 Q. I asked if you perform them?

14 A. ■ supervise autopsies. Just as at hospitals like
15 the Cleveland Clinic and University Hospitals we have
16 residents who -- when we had our own residency program
17 our residents would do the autopsies. As the
18 pathologist on call ■ would review the autopsy with
19 them, review the pathology and review the case with
20 them.

21 More recently since we discontinued our
22 residency program, we have residents from other
23 institutions come and do the autopsies for us. We
24 fulfill the same role.

25 Q. when did you first come to Mount Sinai?

1 A. 1987.

2 Q. In 1987 was there a residency program in pathology
3 at Mount Sinai?

4 A. Yes.

5 Q. When did that program cease to exist?

6 A. The program ceased to exist at the end of June,
7 1997.

8 Q. So for a 10 year period there was a pathology
9 residency program. If I'm understanding your testimony,
10 under the auspices of that program the residents
11 performed autopsies, correct?

12 A. Yes.

13 Q. what percentage of your time would you say in that
14 10 year period was actually devoted to I think you used
15 the word supervising, is supervising a fair word?

16 A. Supervising, overseeing, working with the
17 residents as they did the autopsy, they did the
18 prosection as we call it.

19 Q. Correct.

20 A. We would review everything. What percentage of my
21 time at that point was involved in autopsies?

22 Q. um-hum.

23 A. 2 to 5 percent, 5 percent.

24 Q. At that time there was a pathology group at the
25 hospital that you were a member of, or were you --

1 A. There always has been.

2 Q. You weren't an employee of the hospital, there was
3 an established I would guess primary pathology group
4 here?

5 A. There has been a pathology group here at the
6 hospital since I joined here, since I came here in '87.

7 Q. Was there someone else in the group who spent more
8 time supervising the residents in the performance and
9 interpretation of autopsies?

10 A. We did it on an on call rotational basis. As I
11 always preach, everything eventually evens out. No, we
12 all did the same.

13 Q. You have not since becoming a doctor served as a
14 coroner; is that a fair assessment?

15 A. That's correct.

16 Q. If I read your CV correctly you are Boarded in
17 anatomical pathology.

18 A. Correct.

19 Q. Please describe for me the subspecialty of
20 anatomical pathology?

21 A. Anatomic pathology is the area of pathology that
22 includes autopsy pathology, surgical pathology and
23 cytology.

24 Q. You are not ■ gather from reading your CV Boarded
25 in forensic pathology?

1 A. Correct.

2 Q. Do you understand or can you explain what the
3 subspecialty of forensic pathology is?

4 A. Forensic pathology covers a wide range of areas
5 that include the evaluation of cause of death in
6 instances of -- how do I want to word it -- abnormal
7 death, homicide, suicide, et cetera. It includes
8 toxicology, some aspects of that as pertains to death.
9 In cases where circumstances surrounding cause of death
10 are not known, a case would be referred to a coroner to
11 perform that.

12 Now in the hospital setting we perform
13 many autopsies that are so-called coroner cases, that
14 are cleared by the corner for us to perform. Yes, we do
15 perform certain corner's cases on behalf of the coroner.

16 Q. How many autopsies did you personally perform last
17 year?

18 A. As a supervisor for residents?

19 Q. urn-hum.

20 A. I don't know the exact number, I would think it
21 would probably be between maybe six and 10.

22 Q. would that number be -- when I said last year, I
23 meant '98. Just for clarification, your year, PGY 1
24 year is June to June maybe?

25 A. '98 I would think somewhere between six and 10.

1 Q. For the five years preceding that would the number
2 be relatively the same or not?

3 A. would have been greater. somewhat greater.

4 Q. That's because you still had your own in-house
5 residency program?

6 A. No, had nothing to do with the residency program.
7 The autopsy rate has slid somewhat over the last five
8 years.

9 Q. Do you have any idea why that is true?

10 A. Census at this hospital is a little lower, we
11 don't ask for the autopsies, we perform autopsies when a
12 permit is obtained. There are a lot of factors. Five
13 years ago the autopsy rate at this hospital was
14 somewhere in the region of 120, 125 a year, it's down
15 significantly from that.

16 Q. Doctor, I didn't see it in your report, or the
17 letter from M. Groedel, so I need to ask, are you going
18 to offer an opinion as to cause of death of Mr. Brown?

19 A. Yes.

20 Q. Please tell me to a reasonable degree of medical
21 probability, what is your opinion as to the cause of
22 death in Lawrence Brown?

23 A. From what I have seen in the medical record, from
24 what I have seen in my review of the slides, I think
25 that Mr. Brown's death is really a multifactorial one.

1 He has severe lung disease, he is
2 emphysematous, he has pulmonary arterial hypertension.
3 He has evidence of longstanding pulmonary
4 thromboembolism that certainly goes back months and may
5 go back even years, up to and including this more recent
6 significant or large pulmonary thromboembolus mentioned
7 in my report.

8 3he has severe cardiac disease. He is
9 in severe heart failure, he has marked cardiomegaly.
10 His heart is very large, I believe it was if not exactly
11 700 grams, it was in the region of 700 grams. He has
12 had high blood pressure, he has coronary artery disease,
13 which has produced both remote and recent myocardial
14 infarctions and necessitated a recent angioplasty
15 followed by bypass graft.

16 He obviously has compromised generalized
17 circulation because he went into renal failure or
18 develop compromised renal function during the course of
19 this most recent illness. It's my opinion that his
20 death is due to a combination of recent organizing large
21 pulmonary thromboembolus, superimposed on longstanding
22 pulmonary thromboembolism, with heart failure, and
23 coronary artery disease, that has contributed to the
24 heart failure.

25 Q. Let me go back, retrace. My handwriting is

1 horrendous, perhaps I can read what I wrote.

2 You said he has severe lung disease, can
3 you -- I don't want to use the word quantify initially,
4 qualify what type of lung disease you believed he had
5 when he came to University Hospitals in May of 1997?

6 A. well, I think I enumerated those. He had
7 emphysema, with emphysematous bullae, he's been a four
8 pack a day smoker for I forget how many years, he has
9 chronic lung disease from smoking, he has pulmonary
10 arterial hypertension, significant pulmonary
11 hypertension.

12 Q. The pulmonary hypertension is caused by the
13 underlying lung disease; do you agree with that or not?

14 A. I think pulmonary hypertension in his case was a
15 combination of we know the emphysema, yes, in part due
16 to that; in part also to the longstanding
17 thromboembolism which certainly contributed to the
18 pulmonary arterial hypertension.

19 Q. That is an aspect that compromised his health,
20 would have been caused by emphysema related to smoking;
21 could you agree that probably would have accounted for
22 the emphysema found in the lungs?

23 A. Yes.

24 Q. He has severe pulmonary hypertension which in all
25 probability was caused by the fact he embolized into his

1 lung sometime prior to coming to the hospital. I want
2 to make sure I'm understanding what you are saying.

3 A. Yes. A combination of longstanding
4 thromboembolism and emphysema.

5 Q. An autopsy prepared --

6 A. If ■ could add to that.

7 Q. Sure, that is okay.

8 A. The heart failure contributed to the ongoing
9 pulmonary hypertension as well.

10 Q. when you say heart failure, right-sided heart
11 failure, left-sided heart failure, or does it matter?

12 A. Both. The commonest cause of right-sided heart
13 failure is left-sided heart failure. Both therefore
14 contributed to the pulmonary arterial hypertension.

15 Q. Is it within your medical knowledge to confirm or
16 deny the most common cause of right-sided heart failure
17 is lung disease?

18 A. The most common cause of right-sided heart failure
19 is secondary to left-sided heart failure, but
20 right-sided heart failure is also a consequence of
21 chronic lung disease, yes.

22 Q. I'm not going to pull it out, we will see if you
23 can remember, the prosector in Mr. Brown's case was I
24 believe a nice young female pathologist Erica someone?

25 A. Erica Wilson.

1 Q. I forgot her last name.

2 she found cor pulmonale, do you have an
3 opinion as to whether cor pulmonale was in existence?

4 a. cor pulmonale is right-sided heart failure. I
5 think I've enumerated that he had emphysema,
6 longstanding thromboembolism.

7 Q. another factor you listed in your multifactorial
8 dissertation was cardiomegaly, enlarged heart?

9 a. I think I said heart failure.

10 Q. Maybe I just didn't get that.

11 You're indicating high blood pressure,
12 in what way did the high blood pressure contribute to
13 his ultimate death?

14 a. High blood pressure we know contributes to heart
15 failure, the end result of high blood pressure is heart
16 failure, so the large size of his heart, the very large
17 size of his heart is due to both left-sided and
18 right-sided failure. We explained the right-sided
19 failure, chronic lung disease, he has left-sided disease
20 as well.

21 He ~~is~~ a hypertensive patient, also has
22 ischemic heart disease with significant infarct
23 involving left and right ventricles. There ~~is~~ another
24 contributing factor to the heart failure.

25 Q. I gather you recently had the opportunity to read

1 the university Hospitals record, recently since January
2 but before Mr. Groedel sent me this letter regarding
3 your new opinions?

4 A. The University Hospitals' record, yes.

5 Q. could you determine based upon the copy of the
6 record that you received as to whether or not Dr. Lee,
7 the attending cardiothoracic surgeon for Mr. Brown
8 had -- could you determine whether or not within the
9 four days preceding Mr. Brown's death that Dr. Lee was
10 of the opinion that Mr. Brown was stable from the
11 cardiac point of view?

12 A. I don't recall that specifically, that specific
13 comment.

14 Q. Do you believe that for the four days preceding
15 his ultimate demise that there was clear evidence in the
16 chart that he was unstable from the cardiac point of
17 view; do you recall that?

18 A. I don't recall specifics. Certainly preterminally
19 there was evidence of heart disease, arrhythmia, slowly
20 falling blood pressure.

21 Q. When you say preterminally, I'm sorry?

22 A. I forget the exact time frame prior to death, I
23 believe he died on the 4th.

24 Q. On the morning of the 4th of June.

25 A. In the morning of the 4th, it would be that night.

1 Q. I would like to ask you if you have a recollection
2 of reading the note contained in the chart. I'll show
3 [redacted] to you, this one eventually highlighted 6-3-97,
4 3:00 p.m., ultrasound evaluation of the heart?

5 A. I don't recall specifically seeing that particular
6 note.

7 Q. Are you able to read this note?

8 A. Not everything.

9 Q. The parts that you are able to read, what does it
10 demonstrate to you about Mr. Brown's heart function at
11 that time?

12 A. Doppler study of the left --

13 Q. Internal?

14 A. Mammary artery graft, left internal mammary artery
15 demonstrate5 triphasic wave pattern. I'm not sure
16 exactly what that implies. Systole peaks,
17 quantitatively less, I don't know what that implies. I
18 can't read the next word, something on the right only,
19 minimal diastolic flow demonstrated, discussed with
20 Dr. Lee.

21 Q. You are not able to interpret that cardiology
22 language, that is what are you telling me?

23 A. I'm not a cardiologist, I would not comment on
24 specifically what that means.

25 Q. There is another note which I would like you to

1 look at, ■ want to ask you a question about that.

2 Immediately following that progress note
3 there, 6-4-97, it looks like would you agree with me
4 5:00 in the morning we can't always read the handwriting
5 precisely from the copies.

6 A. 0500, yes.

7 Q. About 5:00 in the morning basically says CTSP for
8 intubation secondary to impending respiratory failure.
9 Do you have an opinion what the cause of the impending
10 respiratory failure was at that moment, based upon your
11 training as a pathologist?

12 A. ■ think again as I indicated that based on what I
13 have seen and based on what was found at autopsy, it is
14 my opinion it was a multifactorial process.

15 Q. when you say it's multifactorial, so I'm not
16 surprised at trial, what was the primary contributing
17 factor as to the cause of death, if you are able to
18 discern one?

19 A. It gets back to what I said, here is a man in
20 heart failure, with a recent infarct, recent bypass
21 surgery, who has emphysema, pulmonary arterial
22 hypertension, has a significant major organizing
23 pulmonary thromboembolus, taken together these are all
24 contributing to impending respiratory failure,

25 Q. So in answer to my question, I know I sound like

1 I'm picking, I need to know if I ask you at the trial,
2 if you are asked would you say they are equally
3 contributory to his death?

4 .MR. GROEDEL: objection. You can
5 answer if you can.

6 A. I don't know how you can answer equally
7 contributory. You are asking me if half of those
8 factors are contributing equally. I think they
9 contribute in concert. They contribute together.
10 You've got someone with poor pulmonary blood flow due to
11 thromboembolism, arterial hypertension, the blood
12 getting into the lungs is poorly oxygenated,
13 emphysematous. Blood flow suggests a heart failure, the
14 pump isn't working at full capacity. Those all
15 contribute together.

16 Q. Even though you haven't seen the deposition of
17 Dr. Downs, have you been made aware of what Dr. Downs
18 testimony is?

19 A. No.

20 Q. If a person has an O₂ HTD of 75, what does that
21 tell you about their physical status?

22 MR. GROEDEL: on room air?

23 Q. On mask, let's put it that way?

24 MR. GROEDEL: How much oxygen?

25 MISS KOLIS: I don't know. I'm

1 asking what he needs to know first.

2 A. He's not well oxygenated, you know, I'm not an
3 intensivist, I don't hold out to be one, he's not well
4 oxygenated, that much is apparent.

5 Q. You told me that you're not an intensivist -- not
6 a cardiologist, I want to be sure about this.

7 Your opinion as to his cause of death is
8 based upon autopsy findings and what clinical
9 information?

10 A. It is based on autopsy findings, it is based on
11 the overall picture and data in the chart that would
12 indicate that a patient -- we know he's had remote and
13 recent infarcts, we know that clinically by history and
14 absolutely by fact at autopsy there is evidence of it.
15 We can see it. We know that,
16 we know he's in heart failure, we know
17 that clinically. We know that from the pathologic
18 standpoint. We can see at autopsy that he has emphysema
19 and we know that there is evidence that he was in fact
20 poorly oxygenated.

21 We know that he has a large pulmonary
22 thromboembolus that is now organizing, we've seen that.
23 We were able to study it and know how large it is, where
24 it's located, the fact that it's organizing. when we
25 put all that together, which is what we do as

1 pathologists, we come up with a clinical, pathologic --
2 we're able to correlate and tie together what we know
3 clinically and what we find pathologically.

4 Q. If the cardiothoracic surgeon in this case, who
5 was the attending for Mr. Brown, indicated that the
6 cause of death was a pulmonary embolus, would you
7 disagree with that opinion, if he so rendered it?

8 MR. GROEDEL: objection, asked and
9 answered. Go ahead.

10 MISS KOLIS: I didn't ask him
11 that question.

12 A. I don't know what he based that opinion on, I
13 can't answer that question.

14 Q. Do you defer to the attending to evaluate the
15 clinical information in conjunction with autopsy
16 information in reaching that conclusion?

17 A. We do autopsies in order to accurately and better
18 define the pathologic processes that were taking place.
19 That is why we do the autopsy. He had a pulmonary
20 embolus, we know that.

21 It was a large pulmonary embolus, it's
22 organizing saddle type of embolus, the clinical data
23 supports that in terms of oxygenation and perfusion,
24 that is documented in the chart. So from a clinical
25 standpoint, the clinicians knew that this patient had

1 had thromboembolism, but the autopsy is done to
2 accurately define site, location, size, duration, time
3 frame, et cetera.

4 Q. Do you know anything about the treatment of
5 pulmonary embolisms?

6 A. Specifically or in general ity?

7 Q. I guess, first of all, you are not going to
8 render, I think Marc made that clear, I always cover the
9 ground on the questions, you won't be rendering an
10 opinion as to appropriateness of the interventions that
11 occurred?

12 A. No.

13 Q. Do you have an opinion to a reasonable degree of
14 medical probability as to whether or not Mr. Brown threw
15 another embolus on the morning of June 4th?

16 A. Yes, I do have an opinion.

17 Q. what is your opinion?

18 A. My opinion is that there is no evidence at autopsy
19 that he did.

20 Q. No evidence meaning you were looking for fresh
21 clot?

22 A. Looking for evidence of a new embolus, a fresh
23 embolus prior to death.

24 Q. Let me ask you the question, it won't be very
25 artful, we will work on it.

1 You are aware that there was a study
2 done the day before on Mr. Brown that detected old and
3 acute clots in the groin area; are you aware of that
4 study?

5 A. There was a study that had shown thrombus
6 within -- I forget specifically which femoral veins, on
7 the left side I believe.

8 Q. So you were aware of that?

9 A. Yes.

10 Q. Do you agree medically that **it** is possible for
11 some of the old clot in that region to dislodge and to
12 go into the pulmonary artery?

13 A. Yes.

14 Q. Do you agree that **if** the clot which was old went
15 into the pulmonary artery that **it** wouldn't have the
16 appearance of acute clot?

17 A. Yes.

18 Q. How do you know that did not happen in this case?

19 A. Because there is no evidence of such a
20 different -- there is no evidence of embolus different
21 from and separate from the organizing embolus in the
22 pulmonary artery. That may be very clumsy.

23 At autopsy the only evidence is that of
24 an organizing large thromboembolus that I've described
25 and told you about, in the pulmonary, saddle type

1 embolus involving both the right and left pulmonary

8 A. Those were the percentages given, yes.

9 Q. Do you have an opinion as to whether or not ~~it~~
10 possible for the person to have one, whether ~~it~~ is left
11 or right 80 percent and the other 90 percent and still
12 be alive?

13 A. ~~Is~~ ~~it~~ likely -- I forget your question. Is ~~it~~
14 possible or is ~~it~~ likely?

15 Q. We'll start with the word possible.

16 A. In this case, at the time of autopsy ~~it~~ was deemed
17 that those vessels were 80 to 90 percent occluded, he
18 died. He presumably had lived with a significant
19 occlusion for a period of time.

20 Q. If so I understand the math and the days, is ~~it~~
21 your testimony today that 80 and 90 percent occlusion ~~in~~
22 left and right pulmonary artery had been in existence
23 for 10 days?

24 A. No.

25 Q. How long do you think that had been in existence?

1 A. I don't know exactly how long the 80 to 90
2 percent. what was found at autopsy is a large
3 organizing thromboembolus that shows an ongoing process
4 of organization, from the point of attachment of the
5 clot to the vessel wall, all the way through to the
6 central portion of the blood clot.

7 Q. I don't know that that answered my question. Let
8 me try it again.

9 First of all, as a pathologist are you
10 aware of any studies that discuss compromise of the left
11 and right pulmonary arteries and what that means in
12 terms of possibility to survive?

13 A. Am I aware of studies of compromise, specific
14 studies?

15 Q. um-hum.

16 A. I'm not quite sure what you mean. In terms of
17 degree of blockage or occlusion?

18 Q. Right, exactly.

19 A. No.

20 Q. The question that I had asked you, hoping to
21 receive an answer, was if he was blocked 80 to 90
22 percent, left/right, we don't have the autopsy right in
23 front of us, I asked you if he had been blocked in the
24 left and right pulmonary arteries for 10 days or more at
25 that percentage of occlusion?

1 A. No.

2 MR. GROEDEL: I think he answered
3 that.

4 A. My answer was no.

5 Q. I understood that answer. So I want to know then
6 was he continuing to embolize within 10 days prior to
7 his death that there was an accumulative effect in the
8 left and right?

9 A. I don't think it is accumulative effect of a
10 repeated embolism. I certainly can't exclude the
11 possibility that following the first embolus that
12 occurred, I've said here two weeks old -- let me go back
13 and say that at a point subsequent to that first embolus
14 two weeks previously, that another emboli had occurred.
15 However, the process of organization that is taking
16 place here is really an ongoing one. One can track the
17 organization as I said all the way really from outside
18 the vessel wall, one can see the inflammation through
19 the vessel wall into the blood clot.

20 When a blood vessel, be it pulmonary
21 artery or peripheral blood, a renal artery, femoral
22 artery is partially occluded and blood flow is altered
23 because of that in a patient who may be hypercoagulable,
24 new blood clot continues because of sludging, new blood
25 clot continues to sort of layer itself on the old blood

1 clot.

2 A perfect example of that would be a
3 blood clot that forms on an anastomosis, at the bypass
4 graft anastomosis, those clot up because maybe a tiny
5 kink in a vessel even produced an alteration of laminar
6 blood flow, due to the turbulence of the blood with
7 partial obstruction one gets blood clot building up. It
8 is common for a patient with emboli, pulmonary artery
9 emboli, systemic thrombi to progressively increase the
10 degree of vascular occlusion due to the slow progressive
11 buildup of blood clot based upon the pattern of
12 organization of the blood clot. It's my opinion that's
13 exactly what occurred in this case.

14 Q. I'm going to ask you some other questions. We
15 will see which I think are really important I suppose.

16 When Mr. Brown came into the hospital,
17 I'm assuming because it was in your testimony, that you
18 were aware that he had pulmonary hypertension, correct?

19 A. It is indicated in the medical record.

20 Q. At the time he had his bypass that was clear or
I'm stating that, do you agree it was clear at the time
22 of his bypass, that he did have pulmonary artery
23 hypertension?

24 A. Pulmonary artery hypertension isn't a sudden
25 condition, so, yes.

1 Q. Do you have an opinion that you'll be offering as
2 to the cause of the pulmonary artery hypertension that
3 existed at the time of bypass graft?

4 A. We have been over a few times that he has
5 emphysema, he's had pulmonary thromboembolism.

6 Q. Based upon your recollection of the records, how
7 would you characterize the degree of pulmonary
8 hypertension Mr. Brown had at the time of his bypass?

9 A. I don't recall whether I would characterize it as
10 moderate or severe pulmonary hypertension, it was
11 certainly significant.

12 Q. Based upon clinical information and/or the
13 pathology slides, can you tell us in terms of the clots
14 in the lung what percentage were chronic, what
15 percentage were acute, meaning within a week to two
16 weeks of the time of his death?

17 A. I couldn't quantify that. There were a number of
18 old pulmonary artery webs, which are old, remote,
19 months, years; there were new small pulmonary arteries,
20 arterials that had fresh embolus in them.

21 Then there is in the right and left
22 there is a saddle embolus that sort of extended into the
23 main branch and the main branch of the pulmonary artery
24 with some smaller fresher blood clots as well distal to
25 that.

1 Q. Doctor, do you have an opinion as to the cause of
2 the pulmonary emboluses, plural, found in the lungs?

3 A. which ones, all of them?

4 Q. All of them.

5 A. well, the saddle type embolus would have had its
6 origins from the deep veins somewhere. There are
7 studies which have shown femoral vessel thrombosis, so
8 that would certainly be a source.

9 As I've indicated, I think an ongoing
10 process of thrombosis overlying the saddle embolus has
11 contributed to the extent of occlusion that was found at
12 autopsy. And the little, the small fresh emboli that
13 one sees in smaller vessels are small bits of fresh
14 thrombus that have just sort of broken free from the
15 surface of the organizing large saddle embolus, that
16 have showered more distally. He has evidence distally
17 of old remote emboli as well.

18 As I said, there is an evidence this has
19 been in this process for a long period of time, probably
20 years.

21 Q. In the autopsy report Dr. Van DePol makes
22 reference to acute infarction of the posterior
23 ventricle; do you recall that?

24 A. Yes.

25 Q. Do you have an opinion when that infarction

1 occurred?

2 A. I've not looked at those slides. I have read
3 Dr. Van DePol's opinion, before rendering an opinion ■
4 would certainly like to look at those slides, review the
5 slides and come to my own conclusion.

6 Q. I guess ■ have two questions about that.

7 ■ assume then it's your testimony that
8 based upon the gross microscopic information contained
9 in the autopsy you personally couldn't reach a
10 conclusion as to when the right posterior ventricle
11 infarcted?

12 A. Other than reading the microscopic description by
13 Dr. Van DePol in the autopsy report, together with his
14 testimony that this was a recent infarct with evidence
15 of remote infarct in the posterior wall of the left
16 ventricle as well.

17 Q. You just indicated you had not seen the heart
18 slides, do you feel you need to see them to render a
19 competent opinion in this case? Can you do so without
20 actually seeing the heart slides?

21 A. If the question I'm being asked is how old was
22 infarct in the right ventricle, ■ would like to look at
23 that the slide, make up my own mind on that.

24 Q. Does the age of the infarct have any bearing on
25 your ultimate opinion as to the cause of death in this

1 case?

2 A. As to the fact that this patient has heart failure
3 and a whole host of factors we discussed, no.

4 Q. I think the answer is fair enough.

5 When someone indicates in an autopsy
6 that something is focally transmural, what does that
7 mean to you?

8 A. well, focal means in part, transmural means
9 through the wall. So there was an old infarct, that in
10 part involved the full thickness of the posterior wall
11 of a left ventricle.

12 Q. The left ventricle infarct, do you have an opinion
13 as to the age of that?

14 A. All I've read is remote.

15 Q. So you don't really have any information?

16 A. I haven't looked at the slide.

17 Q. You haven't looked at the slide, the word used was
18 remote, that doesn't tell you how long ago that
19 infarction occurred; is that correct?

20 A. It doesn't tell me exactly. If we're using the
21 term remote it usually implies that there was old healed
22 infarct, certainly at the very least many weeks, several
23 weeks, many months or even years. All I know is that
24 there was a remote infarct.

25 Q. Mr. Groedel asked Dr. Wecht a good question at his

1 deposition, I want to borrow the same.

2 MR. GROEDEL: Just one?

3 MISS KOLIS: Just one. I
4 couldn't believe it. Just teasing.

5 THE WITNESS: Even a blind
6 squirrel finds an acorn occasionally.

7 Q. Have you taken photomicrographs of the slides in
8 this case?

9 A. Yes.

10 Q. Are you going to go blow them up, use them at the
11 trial?

12 a. I'm not going to blow them up. I've given them to
13 Mr. Groedel, he's going to decide to use photographs,
14 use the slides, make prints, whatever,

15 Q. I'm just curious. That's fine.

16 When writing an autopsy report and
17 discussing embolus, when you use the word resolved, what
18 do you mean?

19 MR. GROEDEL: Resolved or
20 resorbed?

21 Q. Resolved?

22 A. If I use the word resolved?

23 Q. Right.

24 A. For me the term resolved means it goes away or it,
25 you know -- resolved means goes away, disappears. I

1 don't believe I used that term.

2 Q. I would gather that you use the term however
3 resorbed?

4 A. I used the term and do use the term resorbed.

5 Q. What does resorbed mean to you?

6 A. I suppose reabsorbed is a variant of resorbed in
7 some respects. Again I'm going to answer it you're
8 asking me in terms of a blood clot?

9 Resorbed means -- with regard to the
10 blood clot it becomes incorporated into the wall of the
11 vessel, granulation tissue, organization reduces the
12 amount of blood clot present. That blood clot
13 eventually becomes sort of incorporated into the wall of
14 the vessel, those webs that you've read about in the
15 autopsy report are the sort of last indication that the
16 blood clot was present there. One ends up with a band
17 of scar tissues in the vessel with the rest of the clot
18 having been resorbed.

19 Q. How long does a blood clot have to be in the lungs
20 before we see evidence it's organizing?

21 A. Blood clot in the lung is no different than blood
22 clot in most other vessels, it depends on what degree of
23 organization you are talking about.

24 Q. How do we categorize degree of organization of a
25 blood clot in the lung?

1 A. The earlier organization which is sort of the
2 adherence of blood clot to the wall, and the ingrowth of
3 small capillaries probably starts sometime around
4 four days, three to four days maybe at the earliest,
5 earliest sort of biochemical -- that is not right term.
6 The earliest phase before we can see it microscopically
7 may be two, three days. By the time we see little
8 capillaries growing into a blood clot we're talking
9 somewhere in the region of four days.

10 Q. Do signs of organization begin immediately after
11 the clot arrives in the lungs?

12 A. Do signs of organization?

13 Q. Right.

14 A. well, I really don't know how to answer that
15 question because organization starts once the blood clot
16 becomes adherent to the vessel wall. That can be
17 anywhere 36, 48 hours, it sort of adheres to the vessel
18 wall, the endothelial cells provide the basis for which
19 the small blood vessels grow in. We don't see that
20 under a microscope until probably as I said four days or
21 so.

22 Q. Can I have your definition of what is meant by
23 characteristic lines of Zahn's?

24 A. Lines of Zahn's are bands or zones that we see in
25 a thrombus that include sort of bands of fibrin mixed

1 with red blood cells, that is what a line of Zahn's is.

2 Q. How soon after the blood clot arrival in the lung
3 would we begin to see lines of Zahn's?

4 A. One can see lines of Zahn's probably somewhere
5 within 18, 24 hours after a blood clot forms.

6 Q. Will those lines go away over a period of time?

7 A. Ultimately as the blood clot sits there, yes, the
8 lines of Zahn's will disappear because the red blood
9 cells will eventually lyse, disappear, and new fibrin
10 will be laid down.

11 Q. Once again, do you have an opinion as to the time
12 frame?

13 A. Ongoing.

14 Q. So at trial if that question gets asked you're not
15 going to name a precise amount of time, six hours, 24,
16 you are going to say ongoing?

17 A. ■ you are talking about single blood clot, you
18 may start seeing lines of Zahn's appear maybe even 12
19 hours after it forms if there are no other physiologic
20 factors involved. Unfortunately that is very rare, you
21 don't get a blood clot, then nothing happens after that,
22 you get a blood clot, new clot forms over it. This is
23 unfortunately fact.

24 One may see new lines of Zahn's for a
25 period of maybe 24, 48 hours, after which yes, the lines

1 of zahn's, the blood hemolyzes, the blood clot becomes a
2 fibrin clot, eventually starts organizing.

3 Q. Do you agree that at the time of autopsy that no
4 pulmonary infarcts were found?

5 A. I did not see any in the slides that were sent to
6 me.

7 Q. What is your training in pulmonology?

8 A. I have no formal training in pulmonology.

9 Q. Do you agree with the following statement: The
10 only significant atherosclerosis noted at time of
11 autopsy is one coronary artery about 50 percent in the
12 LAD?

13 A. You know, again the slides that were sent to me,
14 just the one section that was about 50 percent, based on
15 the report of Van DePol, Dr. Van DePol, yes, I saw
16 nothing that indicated a greater extent than that.

17 Q. Given Mr. Brown's level of pulmonary compromise
18 prior to the morning of June 4th, hypothetically what
19 degree of additional embolization would you think it
20 would take to have him have a terminal event?

21 Let me ask it again. Given the degree
22 of pulmonary compromise that existed in this patient
23 prior to the morning of June 4th, are you with me? I
24 think you are.

25 A. Okay.

1 Q. Do you have an opinion as to what amount of
2 additional embolus it would have taken to have caused a
3 terminal event in this patient from an embolus?

4 A. I have no idea. He was compromised cardiac-wise,
5 he was compromised pulmonary-wise. He has a large
6 organizing thromboembolus, I really can't say how much,
7 how large, quantify what specific additional factors
8 would have precipitated cardiopulmonary failure.

9 Q. would you defer to the judgment of a Board
10 certified pulmonologist and his ability to answer that
11 question?

12 A. I don't know that that question can be answered.
13 I'm unable to tell you that it would have taken another
14 embolus 1 millimeter, that can't be answered. I think
15 there are so many other factors going on.

16 Q. In your review of the chart were you looking on
17 the evening and morning of June 3rd and June 4th for
18 clinical evidence of additional embolus, clinical not
19 pathology obviously?

20 A. I looked through the records, certainly. Was I
21 looking specifically to see if there was an acute
22 embolus, in looking through the record I see no evidence
23 of a specific acute event that produced cardiopulmonary
24 arrest. It was rather a decline, blood pressure fell,
25 he became hypotensive, he had arrhythmias, then couldn't

1 be resuscitated. I did not see an acute event of sudden
2 collapse.

3 Q. You've read Dr. Wecht's testimony I'm assuming a
4 little while ago, right?

5 A. Yes.

6 Q. Do you know Dr. Wecht?

7 A. I know who he is, I don't know him personally.

8 Q. Never had an opportunity to speak with him for any
9 particular reason?

10 A. No. I'm not invited to appear on Geraldo Rivera
11 so I would not have spoken to him.

12 Q. Doctor, one of his bases for his opinion is the
13 fact that Mr. Brown did not respond to CPR mitigates
14 against this being heart failure; do you agree or
15 disagree with that opinion?

16 A. could you repeat that? Sorry.

17 Q. sure. I'll try to read it in context so I don't
18 misread it. Part of Dr. Wecht's testimony was of course
19 opinion testimony, he attempted to give his basis for
20 his beliefs.

21 He indicates the clinical picture, that
22 the dramatic nature and unresponsiveness to CPR are all
23 so very consistent with massive bilateral pulmonary
24 embolus you can't do anything about it; do you agree
25 with that statement?

1 MR. GROEDEL: I'll object. Go
2 ahead, you can answer.

3 A. A massive fresh pulmonary embolus often times you
4 can't do anything about it. You know your question
5 initially had something to do with the fact that the
6 patient couldn't be resuscitated mitigated against this
7 being a cardiac death. If that was the fact, no patient
8 would ever die of heart failure, which is ridiculous.

9 Q. You had answered earlier that it is possible for
10 old clot found in the veins to find its way up to the
11 pulmonary artery, correct?

12 A. It is possible. usually blood clot that embolizes
13 is fresh, unattached, not organized blood clot.
14 Especially where there is no trauma involved. Once
15 blood clots starts organizing, it's attached to the
16 vessel wall, it takes something to knock a piece of that
17 off.

18 Q. You also, so that I'm perfectly clear about it,
19 testified that if in fact that is what occurred, it
20 would appear as a recognizable separate entity in the
21 pulmonary artery?

22 A. Yes.

23 Q. Just a couple more minutes.

24 A. okay.

25 Q. What is your explanation as to why there are no

1 infarctions, pulmonary infarctions in the lungs?

2 A. well, I think what happened in this patient is
3 that he had an embolus that was sizeable, about
4 two weeks before he died; that this embolus started
5 organizing, that blood continued to flow and perfuse the
6 lung, albeit not very well, because we know that; that
7 because blood was continuing to flow he in fact did not
8 infarct.

9 Infarction occurs when a usually
10 segmental pulmonary artery is completely or almost
11 completely occluded, blood flow to a segment, either a
12 large or small segment of lung, is completely cut off,
13 that area infarcts. In this case, it's my opinion that
14 the infarct that developed two weeks prior to his death
15 allowed --

16 MR. GROEDEL: The embolus.

17 THE WITNESS: Embolus.

18 MR. GROEDEL: You said infarct.

19 A. I apologize.

20 The embolus that occurred two weeks
21 before his death obviously did not block the right and
22 left pulmonary artery, he would have died acutely.
23 Blood continued to flow and perfuse the lung. There was
24 no infarct over this period of two weeks while this
25 embolus was organizing, blood clot continued to build

1 up, the pulmonary artery became progressively more
2 occluded, there was ongoing blood flow through the lungs
3 throughout this period of time.

4 Q. Based upon your review of the chart, on what day
5 to a reasonable degree of medical probability should the
6 doctors have recognized that the man was embolizing or
7 had embolized?

8 MR. GROEDEL: objection. I
9 already indicated Dr. Mendelsohn is not going to be
10 rendering opinions at trial with respect to the standard
11 of care.

12 Q. That's fair enough. I hate to beat a dead horse,
13 make sure I don't get surprised.

14 Currently, meaning within the last two
15 years -- how current could that be -- approximately
16 how much medical/legal work are you actually doing?

17 A. You know, I probably get sent maybe 10, 12 cases a
18 year to look at. Maybe a couple more than that. Most
19 of those I don't consider medical/legal work because I
20 look at the slide, I give an opinion, usually a verbal
21 opinion, the answer is thank you very much, could you
22 return the slides, or we will have a courier pick them
23 up. As far as I'm concerned I have looked at a couple
24 of pathology slides. I'm asked probably I think if I
25 said a dozen time a year I wouldn't be too far off.

1 Q. Is it still predominantly lawyers who represent
2 doctors that contact you?

3 A. Yeah, predominantly.

4 Q. I'm aware you testified for I believe Eric
5 Kennedy, Mr. Scanlon in Akron, anybody else come to
6 mind?

7 A. I've looked at cases for Steve charms, Toby
8 Hirschman.

9 Q. All ex-PIE guys. Anybody else?

10 A. what is his name, Mr. DaPore.

11 Q. Tony DaPore?

12 A. I can't --

13 Q. It's okay.

14 A. A few others.

15 Q. Do you keep -- I can't imagine you do, ■■■■ask
16 anyway -- do you keep records of cases you've worked on,
17 keep any of the reports, things of that nature?

18 A. If cases are current, obviously I've got files.

19 Q. Then you toss it?

20 A. Yeah, if I'm told a case is settled or I'm not
21 asked to pursue it, or do anything, then ■ don't keep a
22 file.

23 Q. would you have -- ■ asked you this earlier in the
24 deposition -- would you have any way of reconstructing
25 for whom you offered testimony in pulmonary embolus

1 cases before?

2 A. Yes, I could go through my records and look at
3 that, sure.

4 Q. I would like for you to provide the information to
5 Mr. Groedel. Assume the following parameters: **If it**
6 was in a case you actually authored a written report, or
7 a case that was filed in court. ■ would like the
8 information under those circumstances. If you find in
9 your review that somebody merely asked your opinion, you
10 didn't write a report, didn't participate in the case,
11 you don't have to provide that.

12 A. okay.

13 Q. Is that fair enough?

14 A. Again, I would just add that **if** a case did go to
15 trial, the case was whatever happened to **it** after trial,
16 I don't keep all those records.

17 MISS KOLIS: That's okay. I'm
18 seeing **if** you can reconstruct -- candidly I'm asking
19 because I've been able to track down a large number of
20 depositions you've given, they are all in cases dealing
21 with cancer pathology, I'm curious **if** you've ever done a
22 PE case.

23 Having said that I'll be ordering a
24 transcript of today's deposition, you know the drill,
25 would you like the read it?

1 THE WITNESS: Yes.

2 MISS KOLIS: ■ can waive the
3 seven day reading requirement but not by much. Today ■
4 September 28th, trial is set for November 1st, could you
5 read it, sign it within 14 days?

6 THE WITNESS: Yes.

7 MISS KOLIS: Does that work?

8 THE WITNESS: That is fine. when
9 will ■ get it though?

10 MISS KOLIS: It's up to how busy
11 she is.

12 THE WITNESS: I'm going away for a
13 few days in the middle of October, if it arrives on the
14 9th, I don't get back until the 12th, no, ■ can't.

15 MISS KOLIS: Doctor indicates he
16 would like to read, ■ have waived the seven days
17 required, asking him to try to deliver it in 14.

18 MR. GROEDEL: Thank you for that.

19 -----

20 (Deposition concluded; signature not waived.)

21 -----

22

23

24

25

1

ERRATA SHEET

2

NOTATIONPAGE/LINE

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

■ have read the foregoing transcript and
the same is true and accurate.

GEOFFREY MENDELSON, M.D.

1 The State of Ohio,
2 county of Cuyahoga. : CERTIFICATE :

3 I, Constance Campbell, Notary Public within and for
4 the State of Ohio, do hereby certify that the within
5 named witness, GEOFFREY MENDELSON, M.D. was by me first
6 duly sworn to testify the truth in the cause aforesaid;
7 that the testimony then given was reduced by me to
8 stenotypy in the presence of said witness, subsequently
9 transcribed onto a computer under my direction, and that
10 the foregoing is a true and correct transcript of the
11 testimony so given as aforesaid.

12 I do further certify that this deposition was taken
13 at the time and place as specified in the foregoing
14 caption, and that I am not a relative, counsel or
15 attorney of either party, or otherwise interested in the
16 outcome of this action.

17 IN WITNESS WHEREOF, I have hereunto set my hand and
18 affixed my seal of office at Cleveland, Ohio,
19 this 1st day of October, 1999.

20 
21 -----

22 Constance Campbell, Stenographic Reporter,
23 Notary Public/State of Ohio.

24 Commission expiration: January 14, 2003.

25

GEOFFREY MENDELSON, M.D.

\$	[2] 25:1 25:2	[2]35:4 35:7	[1] 9:9
\$275	1988	6	Absolutely
[1] 6:14	[1] 24:10	6-3-97	[1] 37:14
'	1997	[1] 34:3	Accept
'80s	[3] 21:2 25:7 30:5	6-4-97	[1] 12:25
[1] 23:6	1999	[1] 35:3	Acceptable
'87	[12] 1:18 6:25 7:	687-1311	[3] 5:11 5:18 6:21
[1] 26:6	5 7:8 7:14 8:6 8:	[1] 2:20	Accordingly
'90s	19 9:2 9:7 9:16	7	[1] 5:15
[1] 23:6	10:9 63:19	700	Accounted
'98	1st	[2] 29:11 29:11	[1] 30:21
[2] 27:23 27:25	[2] 61:4 63:19	75	Accumulative
0	2	[1] 36:20	[2] 43:7 43:9
0500	2	a	Accurate
[1] 35:6	[2] 6:25 25:23	80	[1] 62:22
1	2003	[6]41:6 41:11 41:	Accurately
1	[1] 63:24	1741:21 42:1 42:	[3] 8:21 38:17 39:
1	216	21	2
[2] 27:23 54:14	[2] 2:8 2:20	861-4300	Acorn
1-14-99	24	[1] 2:8	[1] 49:6
[1] 3:10	[3] 52:5 52:15 52:	9	Action
10	25	9	[1] 63:16
[11] 17:11 18:9	27	[1] 8:19	Acute
18:17 25:8 25:14	[1] 7:4	90	[14] 19:3 19:4 19::
27:21 27:25 41:23	28th	[6]41:6 41:11 41:	6 19:7 19:8 19:9
42:24 43:6 58:17	[3] 1:18 9:5 61:4	1741:21 42:1 42:	19:10 40:3 40:16
113	3	21	45:15 46:22 54:21
[1] 2:18	330	9th	54:23 55:1
12	[1] 2:6	[1] 61:14	Acutely
[5] 3:10 17:11 18:	346342		[1] 57:22
9 52:18 58:17	[1] 1:7		Add
120	36		[2] 31:6 60:14
[1] 28:14	[1] 51:17	[18] 62:3 62:4 62:	Additional
125	3:00	5 62:6 62:7 62:8	[6] 13:20 19:24
[1] 28:14	[2] 1:19 34:4	62:9 62:10 62:11	53:19 54:2 54:7
12th	3he	62:12 62:13 62:14	54:18
[1] 61:14	[1] 29:8	62:15 62:16 62:17	Adherence
13	3rd	62:18 62:19 62:20	[1] 51:2
[3] 9:7 9:16 10:9	[1] 54:17	[1] 62:24	Adherent
13th	4		[1] 51:16
[3] 10:21 10:21	44113	[18] 62:3 62:4 62:	adheres
11:11	[1] 2:7	5 62:6 62:7 62:8	[1] 51:17
14	44114	62:9 62:10 62:11	Affixed
[7] 9:2 17:11 18:	[1] 2:19	62:12 62:13 62:14	[1] 63:18
9 18:9 61:5 61:17	88	62:15 62:16 62:17	Aforesaid
63:24	[2] 51:17 52:25	62:18 62:19 62:20	[2] 63:6 63:11
14th	8th	A	Afraid
[3] 10:22 10:25	[7] 33:23 33:24	Ability	[2] 17:3 19:15
12:3	33:25 39:15 53:18	[2]23:2 54:10	
15	53:23 54:17	[9] 14:4 15:25 34:	[5] 4:2 17:1 23:1
[2] 7:14 8:6	5	734:9 34:21 35:	47:24 48:13
15th	13	1737:23 38:2 60:	
[3] 7:21 7:24 8:20	[3] 3:4 25:23 25:	19	[3] 28:13 48:18
16	23	Abnormal	55:4
[1] 7:8	50	[1] 27:6	Agree
18	[2] 53:11 53:14	Above-captioned	[12] 9:21 23:18
[1] 52:5	5:00		30:13 30:21 35:3
1987			40:10 40:14 44:21

GEOFFREY MENDELSON, M.D.

53:3 53:9 55:14 55:24 Agreement [1] 10:23 Ahead [2] 38:9 56:2 Air [3] 15:1 15:3 36: 22 Akron [1] 59:5 Al [1] 1:9 Albeit [1] 57:6 Alive [1] 41:12 Allowed [1] 57:15 Almost [1] 57:10 Alone [1] 15:24 Alteration [1] 44:5 Altered [1] 43:22 Amount [5] 6:15 18:16 50: 12 52:15 54:1 Anastomosis [2] 44:3 44:4 Anatomic [1] 26:21 Anatomical [2] 26:17 26:20 Angioplasty [1] 29:14 Answer [16] 5:3 13:9 21: 6 35:25 36:5 36:6 38:13 42:21 43:4 43:5 48:4 50:7 51: 14 54:10 56:2 58: 71 Answered [6] 38:9 42:7 43: 2 54:12 54:14 56:9 Anyway [1] 59:16 Apologize [1] 57:19 Apparent [1] 37:4 Appear [4] 8:11 52:18 55: LO 56:20 Appearance	[1] 40:16 APPEARANCES [1] 2:1 Appeared [1] 20:24 APPENDIX [1] 3:1.5 Appropriateness [1] 39:10 April [2] 8:6 23:25 Area [5] 23:11 23:17 26:21 40:3 57:13 Areas [4] 23:14 23:15 23:20 27:4 Arena [1] 20:22 Arrangements [1] 6:18 Arrest [1] 54:24 Arrhythmia [1] 33:19 Arrhythmias [1] 54:25 Arrival [1] 52:2 Arrives [2] 51:11 61:13 Arriving [1] 20:3 Arterial [6] 29:2 30:10 30: 18 31:14 35:21 36: 11 Arterials [1] 45:20 Arteries [4] 41:2 42:11 42: 24 45:19 Artery [36] 12:13 12:14 12:14 15:7 15:8 15:20 16:2 16:8 16:17 16:19 16:20 16:21 16:23 29:12 29:23 34:14 34:14 40:12 40:15 40:22 41:22 43:21 43:21 43:22 44:8 44:22 44:24 45:2 45:18 45:23 53:11 56:11 56:21 57:10 57:22 58:1 Artful [1] 39:25	Aspect [1] 30:19 Aspects [1] 27:8 Assessment [1] 26:14 Assistance [1] 23:7 Association [1] 16:16 Assume [3] 17:18 47:7 60: 5 Assumed [1] 12:14 Assuming [2] 44:17 55:3 Assurance [5] 21:8 21:14 21: 19 21:24 22:5 Atherosclerosis [1] 53:10 Attached [3] 15:8 16:22 56: 15 Attachment [1] 42:4 Attempted [1] 55:19 Attending [3] 33:7 38:5 38: 14 Attention [1] 7:5 Attorney [6] 5:9 5:14 5:14 11:18 22:22 63:15 Attorney's [1] 22:14 Attorneys [1] 17:2 August [1] 7:4 Auspices [1] 25:10 Author [1] 17:22 Authored [2] 10:11 60:6 Autopsies [12] 24:11 24:14 24:17 24:23 25:11 25:21 26:9 27:13 27:16 28:11 28:11 38:17 Autopsy [36] 12:10 12:12 18:4 19:5 19:6 20:	8 24:18 25:17 26: 22 28:7 28:13 31: 5 35:13 37:8 37: 10 37:14 37:18 38: 15 38:19 39:1 39: 18 40:23 41:3 41: 4 41:16 42:2 42: 22 46:12 46:21 47: 9 47:13 48:5 49: 16 50:15 53:3 53: 11 Available [2] 20:14 20:15 Aware [10] 11:15 12:4 36:17 40:1 40:3 40:8 42:10 42:13 44:18 59:4 B Backward [1] 9:12 Band [1] 50:16 Bands [2] 51:24 51:25 Based [22] 4:22 11:7 13: 20 14:8 15:24 18: 1 18:12 19:25 33: 5 35:10 35:12 35: 13 37:8 37:10 37: 10 38:12 44:11 45: 6 45:12 47:8 53: 14 58:4 Bases [1] 55:12 Basis [3] 26:10 51:18 55:19 Bearing [1] 47:24 Beat [1] 58:12 Became [2] 54:25 58:1 Becomes [4] 50:10 50:13 51:16 53:1 Becoming [1] 26:13 Begin [2] 51:10 52:3 Behalf [4] 2:2 2:14 4:15 27:15 Beliefs [1] 55:20 Bet
---	---	--	--

GEOFFREY MENDELSON, M.D.

[1] 17:20 Better [1] 38:17 Between [4] 18:9 21:14 27:21 27:25 Bilateral [1] 55:23 Bill [2] 6:9 6:20 Biochemical [1] 51:5 Bits [1] 46:13 Blind [1] 49:5 Block [1] 57:21 Blockage [2] 41:5 42:17 Blocked [2] 42:21 42:23 Blood [62] 16:7 16:21 16:24 17:14 18:13 29:12 32:11 32:12 32:14 32:15 33:20 36:10 36:11 36:13 42:6 43:19 43:20 43:21 43:22 43:24 43:24 43:25 44:3 44:6 44:6 44:7 44:11 44:12 45:24 50:8 50:10 50:12 50:12 50:16 50:19 50:21 50:21 50:25 51:2 51:8 51:15 51:19 52:1 52:2 52:5 52:7 52:8 52:17 52:21 52:22 53:1 53:1 54:24 56:12 56:13 56:15 57:5 57:7 57:11 57:23 57:25 58:2 Blow [2] 49:10 49:12 Board [1] 54:9 Boarded [2] 26:16 26:24 Body [2] 17:8 17:13 Bonnie [1] 11:11 Book [1] 23:20 Borrow [1] 49:1	Branch [2] 45:23 45:23 Breast [1] 23:19 Brief [1] 22:5 Briefly [2] 14:2 14:3 Bring [1] 5:25 Broken [1] 46:14 Brown [12] 1:6 4:14 28:18 28:22 33:7 33:10 38:5 39:14 40:2 44:16 45:8 55:13 Brown's [9] 7:18 18:3 18:23 19:13 28:25 31:23 33:9 34:10 53:17 Build [1] 57:25 Building [3] 2:6 2:18 44:7 Buildup [1] 44:11 Bullae [3] 14:20 15:3 30:7 Busy [1] 61:10 Bypass [7] 29:15 35:20 44:3 44:20 44:22 45:3 45:8	Cardiac-wise [1] 54:4 Cardiologist [2] 34:23 37:6 Cardiology [1] 34:21 Cardiomegaly [2] 29:9 32:8 Cardiopulmonary [2] 54:8 54:23 Cardiothoracic [2] 33:7 38:4 Care [3] 12:25 13:6 58:11 Carriers [1] 21:3 Case [32] 1:7 12:5 13:1 13:7 18:22 19:17 20:25 22:9 22:11 22:16 22:17 22:19 22:23 24:19 27:10 30:14 31:23 38:4 40:18 41:16 44:13 47:19 48:1 49:8 57:13 59:20 60:6 60:7 60:10 60:14 60:15 60:22 Cases [9] 27:9 27:13 27:15 58:17 59:7 59:16 59:18 60:1 60:20 Categorize [1] 50:24 Caused [6] 19:3 19:13 30:12 30:20 30:25 54:2 Cava [1] 18:21 Cease [1] 25:5 Ceased [1] 25:6 Cells [5] 16:15 16:18 51:18 52:1 52:9 Census [1] 28:10 Center [1] 1:17 Central [1] 42:6 Certain [1] 27:15 Certainly	[9] 29:4 30:17 33:18 43:10 45:11 46:8 47:4 48:22 54:2 Certified [2] 4:5 54:10 Certify [2] 63:4 63:12 Cetera [2] 27:7 39:3 Changed [1] 18:6 Changes [1] 17:12 Characteristic [1] 51:23 Characterize [2] 45:7 45:9 Characterized [1] 15:1 Charging [1] 6:16 Charms [1] 59:7 Chart [9] 5:25 6:2 6:7 33:16 34:2 37:11 38:24 54:16 58:4 Chief [1] 24:1 Chronic [7] 14:25 16:15 16:18 30:9 31:21 32:19 45:14 Circulation [1] 29:17 Circumstances [2] 27:9 60:8 Civil [2] 1:15 4:4 Clair [1] 2:18 Clarification [1] 27:23 Clarify [1] 5:10 Clear [5] 33:15 39:8 44:20 44:21 56:18 Cleared [1] 27:14 Clearly [1] 12:11 Cleveland [7] 1:9 1:17 2:7 2:19 14:6 24:15 63:18 Clinic [1] 24:15
C			
	Cancelled [1] 8:20 Cancer [5] 23:15 23:18 23:19 23:19 60:21 Cancers [1] 23:11 Candidly [1] 60:18 Capacity [1] 36:14 Capillaries [2] 51:3 51:8 Caption [1] 63:14 Captioned [1] 9:9 Cardiac [5] 29:8 33:11 33:16 54:4 56:7		

GEOFFREY MENDELSON, M.D.

Clinical [10] 15:25 37:8 38:1 38:15 38:22 38:24 45:12 54:18 54:18 55:21 Clinically [3] 37:13 37:17 38:3 Clinicians [1] 38:25 Clock [1] 17:8 Clot [49] 16:7 16:21 16:25 17:14 18:3 18:13 18:17 39:21 40:11 40:14 40:16 42:5 42:6 43:19 43:24 43:25 44:1 44:3 44:24 44:7 44: 11 44:12 50:8 50: 10 50:12 50:12 50: 16 50:17 50:19 50: 21 50:22 50:25 51: 2 51:8 51:11 51: 15 52:2 52:5 52:7 52:17 52:21 52:22 52:22 53:1 53:2 56:10 56:12 56:13 57:25 Clots [4] 40:3 45:13 45: 24 56:15 Clumsy [1] 40:22 Coincident [1] 24:4 Coinciding [1] 24:4 Collapse [1] 55:2 Combination [3] 29:20 30:15 31:3 Coming [2] 6:6 31:1 Commencing [1] 1:18 Comment [2] 33:13 34:23 Commission [1] 63:24 Common [4] 1:4 31:16 31: 18 44:8 Commonest [1] 31:12 Competent	[1] 47:19 Complete [2] 3:15 20:8 Completely [4] 9:12 57:10 57: 11 57:12 Comport [1] 41:6 Compromise [4] 42:10 42:13 53:17 53:22 Compromised [5] 29:16 29:18 30:19 54:4 54:5 Computer [1] 63:9 Concerned [1] 58:23 Concerning [1] 11:21 Concert [1] 36:9 Concise [1] 4:19 Conclude [1] 16:10 Concluded [1] 61:20 Conclusion [5] 6:19 15:13 38: 16 47:5 47:10 Conclusions [1] 20:4 Condition [2] 14:25 44:25 Confer [1] 5:16 Confirm [2] 21:21 31:15 Congested [2] 14:19 14:24 Conjunction [2] 5:23 38:15 Consequence [1] 31:20 Consider [1] 58:19 Consistent [1] 55:23 Constance [3] 1:15 63:3 63: 22 Contact [1] 59:2 Contacted [2] 9:13 9:17 Contacting [1] 10:12	Contain [2] 12:24 15:7 Contained [5] 6:4 14:3 15: 13 34:2 47:8 Context [1] 55:17 Continued [3] 57:5 57:23 57: 25 Continues [2] 43:24 43:25 Continuing [2] 43:6 57:7 Contribute [4] 32:12 36:9 36: 9 36:15 Contributed [5] 29:23 30:17 31:8 31:14 46:11 Contributes [1] 32:14 Contributing [4] 32:24 35:16 35:24 36:8 Contributory [2] 36:3 36:7 Conversation [1] 9:23 Copies [1] 35:5 Copy [8] 6:8 6:9 7:16 7:25 9:1 12:18 17: 18 33:5 Cor [3] 32:2 32:3 32:4 Corner [1] 27:14 Corner's [1] 27:15 Coronary [4] 12:14 29:12 29:23 53:11 Coroner [4] 26:14 27:10 27:13 27:15 Correct [34] 4:16 4:25 7: 2 7:6 7:7 8:1 8:7 8:9 8:10 8:13 8: 25 9:3 9:10 9:11 13:13 13:19 13:22 13:24 13:25 14:6 14:7 15:11 15:18 18:18 19:21 25:11 25:19 26:15 26:18 27:1 44:18 48:19	56:11 63:10 Correctly [4] 4:9 6:24 15: 10 26:16 Correlate [1] 38:2 Correspondence [1] 7:14 Counsel [1] 63:14 Count [1] 22:10 County [2] 1:2 63:2 Couple [5] 16:5 18:14 56: 23 58:18 58:23 Courier [1] 58:22 Couriered [1] 11:12 Course [4] 4:22 5:2 29: 18 55:18 Courteous [1] 13:15 Courtesy [1] 10:16 Cover [2] 3:17 39:8 Covering [1] 7:18 Covers [1] 27:4 CPR [2] 55:13 55:22 Cross-examination [4] 1:14 3:4 4:3 5:21 CZTSP [1] 35:7 Curious [2] 49:15 60:21 Current [2] 58:15 59:18 Cut [1] 57:12 CV [4] 23:10 23:13 26:16 26:24 Cytology [1] 26:23
D			
			DaPore [2] 59:10 59:11 Data [2] 37:11 38:22 Date

GEOFFREY MENDELSON, M.D

<p>[2] 7:1 9:5</p> <p>Dated</p> <p>[9] 6:25 7:4 7:8</p> <p>9:1 9:7 9:16 10:</p> <p>21 10:25 11:11</p> <p>Days</p> <p>[21] 17:11 17:11</p> <p>17:11 18:4 18:9</p> <p>18:16 18:17 33:9</p> <p>33:14 41:20 41:23</p> <p>42:24 43:6 51:4</p> <p>51:4 51:7 51:9 51</p> <p>20 61:5 61:13 61:</p> <p>16</p> <p>Dead</p> <p>[1] 58:12</p> <p>Dealing</p> <p>[1] 60:20</p> <p>Dealt</p> <p>[1] 22:19</p> <p>Death</p> <p>[24] 14:22 19:3</p> <p>27:5 27:7 27:8 27:</p> <p>9 28:18 28:22 28:</p> <p>25 29:20 32:13 33:</p> <p>9 33:22 35:17 36:</p> <p>3 37:7 38:6 39:23</p> <p>43:7 45:16 47:25</p> <p>56:7 57:14 57:21</p> <p>Decide</p> <p>[1] 49:13</p> <p>Decline</p> <p>[1] 54:24</p> <p>Deemed</p> <p>[1] 41:16</p> <p>Deep</p> <p>[1] 46:6</p> <p>DEFENDANT</p> <p>[1] 2:14</p> <p>Defendants</p> <p>[1] 1:9</p> <p>Defer</p> <p>[2] 38:14 54:9</p> <p>Define</p> <p>[2] 38:18 39:2</p> <p>Definition</p> <p>[1] 51:22</p> <p>Degree</p> <p>[10] 28:20 39:13</p> <p>42:17 44:10 45:7</p> <p>50:22 50:24 53:19</p> <p>53:21 58:5</p> <p>Deliver</p> <p>[1] 61:17</p> <p>Delivered</p> <p>[1] 10:20</p> <p>Delivery</p> <p>[1] 11:11</p>	<p>Demand</p> <p>[1] 41:4</p> <p>Demise</p> <p>[3] 18:23 19:13</p> <p>33:15</p> <p>Demonstrate</p> <p>[1] 34:10</p> <p>Demonstrated</p> <p>[1] 34:19</p> <p>Demonstrates</p> <p>[1] 34:15</p> <p>Deny</p> <p>[1] 31:16</p> <p>Department</p> <p>[2] 23:24 24:7</p> <p>DePol</p> <p>[6] 8:12 8:14 46:</p> <p>21 47:13 53:15 53:</p> <p>15</p> <p>DePol's</p> <p>[2] 20:3 47:3</p> <p>Deposition</p> <p>[25] 1:12 5:2 5:</p> <p>23 6:16 6:19 7:1</p> <p>7:6 7:8 7:10 8:11</p> <p>8:17 8:20 13:17</p> <p>16:14 18:1 19:2</p> <p>20:1 20:6 20:13</p> <p>36:16 49:1 59:24</p> <p>60:24 61:20 63:12</p> <p>Depositions</p> <p>[2] 4:23 60:20</p> <p>Describe</p> <p>[2] 11:23 26:19</p> <p>Described</p> <p>[1] 40:24</p> <p>Describes</p> <p>[1] 12:15</p> <p>Description</p> <p>[1] 47:12</p> <p>Detected</p> <p>[1] 40:2</p> <p>Determination</p> <p>[1] 16:4</p> <p>Determine</p> <p>[3] 16:1 33:5 33:8</p> <p>Develop</p> <p>[1] 29:18</p> <p>Developed</p> <p>[1] 57:14</p> <p>Deviations</p> <p>[1] 12:25</p> <p>Devoted</p> <p>[1] 25:14</p> <p>Diagnostically</p> <p>[1] 11:19</p> <p>Diastolic</p> <p>[1] 34:19</p>	<p>Die</p> <p>[1] 56:8</p> <p>Died</p> <p>[4] 33:23 41:18</p> <p>57:4 57:22</p> <p>Different</p> <p>[4] 20:22 40:20</p> <p>40:20 50:21</p> <p>Diminishing</p> <p>[1] 23:2</p> <p>Direction</p> <p>[1] 63:9</p> <p>Director</p> <p>[3] 23:24 23:24</p> <p>24:7</p> <p>Disagree</p> <p>[2] 38:7 55:15</p> <p>Disappear</p> <p>[2] 52:8 52:9</p> <p>Disappears</p> <p>[1] 49:25</p> <p>Discern</p> <p>[1] 35:18</p> <p>Discontinued</p> <p>[1] 24:21</p> <p>Discuss</p> <p>[1] 42:10</p> <p>Discussed</p> <p>[2] 34:19 48:3</p> <p>Discussing</p> <p>[3] 8:23 19:21 49:</p> <p>17</p> <p>Discussion</p> <p>[2] 7:15 11:9</p> <p>Discussions</p> <p>[1] 12:9</p> <p>Disease</p> <p>[14] 29:1 29:8 29:</p> <p>12 29:23 30:2 30:</p> <p>4 30:9 30:13 31:</p> <p>17 31:21 32:19 32:</p> <p>19 32:22 33:19</p> <p>Diseases</p> <p>[1] 23:20</p> <p>DISK</p> <p>[1] 3:17</p> <p>Dislodge</p> <p>[1] 40:11</p> <p>Disertation</p> <p>[1] 32:8</p> <p>Distal</p> <p>[1] 45:24</p> <p>Distally</p> <p>[2] 46:16 46:16</p> <p>Doctors</p> <p>[2] 58:6 59:2</p> <p>Document</p> <p>[1] 21:22</p>	<p>Documented</p> <p>[1] 38:24</p> <p>Documents</p> <p>[1] 6:7</p> <p>Done</p> <p>[4] 4:23 39:1 40:</p> <p>2 60:21</p> <p>Donna</p> <p>[3] 2:4 2:5 4:12</p> <p>Doppler</p> <p>[1] 34:12</p> <p>Down</p> <p>[3] 28:14 52:10</p> <p>60:19</p> <p>Downs</p> <p>[3] 20:20 36:17</p> <p>36:17</p> <p>Dozen</p> <p>[1] 58:25</p> <p>Dramatic</p> <p>[1] 55:22</p> <p>Drill</p> <p>[1] 60:24</p> <p>Drive</p> <p>[1] 1:17</p> <p>Due</p> <p>[6] 29:20 30:15</p> <p>32:17 36:10 44:6</p> <p>44:10</p> <p>July</p> <p>[2] 4:4 63:6</p> <p>Duration</p> <p>[1] 39:2</p> <p>Luring</p> <p>[3] 5:16 21:23 29</p> <p>18</p>
E			
			<p>Earliest</p> <p>[3] 51:4 51:5 51:</p> <p>Early</p> <p>[2] 16:12 23:6</p> <p>Effect</p> <p>[2] 43:7 43:9</p> <p>Either</p> <p>[2] 57:11 63:15</p> <p>Emboli</p> <p>[5] 43:14 44:8 44</p> <p>3 46:12 46:17</p> <p>Embolism</p> <p>[1] 43:10</p> <p>Embolisms</p> <p>[1] 39:5</p> <p>Embolization</p> <p>[1] 53:19</p> <p>Embolize</p> <p>[1] 43:6</p> <p>Embolized</p> <p>[2] 30:25 58:7</p>

GEOFFREY MENDELSON, M.D.

Embolizes [1] 56:12	[1] 59:4 Erica [2] 31:24 31:25	Exclude [1] 43:10	31:11 31:13 31:13
Embolizing [1] 58:6	Erin [2] 2:14 4:16	Exhibit [2] 12:19 12:21	31:16 31:18 31:19
Embolus [44] 16:10 16:24 17:6 19:4 19:6 19:8 7 19:8 19:8 19:9 19:10 19:12 22:20 38:6 38:20 38:21 38:22 39:15 39:22 39:23 40:20 40:21 41:1 43:11 43:13 45:20 45:22 46:5 46:10 46:15 49:17 54:2 54:3 54:14 54:18 54:22 55:24 56:3 57:3 57:4 57:16 57:17 57:20 57:25 59:25	Especially [1] 56:14 Established [1] 26:3 Estate [2] 1:6 4:13 Et [3] 1:9 27:7 39:3 Evaluate [2] 22:18 38:14 Evaluation [2] 27:5 34:4 Evaluations [1] 6:13 Evening [1] 54:17 Evens [1] 26:11 Event [5] 7:24 53:20 54:3 54:23 55:1 Events [1] 10:24 Eventually [5] 26:11 34:3 50:13 52:9 53:2 Evidence [20] 19:4 19:5 19:7 29:3 33:15 33:19 37:14 37:19 39:18 39:20 39:22 40:19 40:20 40:23 46:16 46:18 47:14 50:20 54:18 54:22	EXHIBITS [1] 3:8 Exist [2] 25:5 25:6 Existed [2] 45:3 53:22 Existence [3] 32:3 41:22 41:25 Expansion [1] 15:1 Expect [1] 4:21 Experience [1] 23:17 Expert [4] 4:15 7:17 9:14 20:24 Expiration [1] 63:24 Explain [1] 27:2 Explained [1] 32:18 Explanation [1] 56:25 Extended [1] 45:22 Extending [1] 16:19 Extent [2] 46:11 53:16 Extremities [1] 19:12	32:15 32:16 32:18 32:19 32:24 35:8 35:10 35:20 35:24 36:13 37:16 48:2 54:8 55:14 56:8 Fair [11] 12:23 13:21 20:25 21:1 23:8 23:12 25:15 26:14 48:4 58:12 60:13 Fairly [1] 23:21 Falling [1] 33:20 Far [2] 58:23 58:25 Features [4] 16:6 16:10 16:23 18:13 Fee [1] 6:12 Fell [1] 54:24 Female [1] 31:24 Femoral [3] 40:6 43:21 46:7 Few [3] 45:4 59:14 61:13 Fibrin [3] 51:25 52:9 53:2 Fibrinous [2] 14:21 15:3 Fibrosis [1] 16:13 Figure [1] 11:6 File [3] 6:24 11:25 59:22 Filed [1] 60:7 Files [1] 59:18 Filing [1] 24:5 Filled [1] 15:3 Filter [1] 18:21 Findings [5] 12:15 14:15
Emboluses [1] 46:2		F	
Emphysema [10] 14:25 30:7 30:15 30:20 30:22 31:4 32:5 35:21 37:18 45:5		Fact [13] 19:8 19:10 30:25 37:14 37:19 37:24 48:2 52:23 55:13 56:5 56:7 56:19 57:7 Factor [4] 20:2 32:7 32:24 35:17 Factors [6] 28:12 36:8 48:3 52:20 54:7 54:15 Facts [4] 4:20 22:23 22:23 23:1 Failure [32] 14:25 29:9 29:17 29:22 29:24 31:8 31:10 31:11	
Emphysematous [6] 14:20 14:20 15:2 29:2 30:7 36:13			
Employee [1] 26:2			
Enclosed [3] 9:8 9:19 10:14			
Enclosing [1] 7:16			
2nd [2] 25:6 32:15			
Endocrine [1] 23:20			
Endothelial [1] 51:18			
Ends [1] 50:16			
Enlarged [1] 32:8			
Entire [1] 12:12			
Entirety [1] 11:25			
Entity [1] 56:20			
Enumerated [3] 16:7 30:6 32:5			
Equally [3] 36:2 36:6 36:8			
Eric			

GEOFFREY MENDELSON, M.D.

14:22 37:8 37:10 Fine [4] 14:14 17:12 49:15 61:8 Firm [2] 22:13 23:7 Firmly [1] 16:22 Firms [1] 22:15 First [17] 4:4 7:21 9: 13 10:2 10:11 10: 16 14:18 20:9 20: 23 24:8 24:25 37: 1 39:7 42:9 43:11 43:13 63:5 Five [3] 28:1 28:7 28: 12 Flow [10] 34:19 36:10 36:13 43:22 44:6 57:5 57:7 57:11 57:23 58:2 Focal [2] 16:14 48:8 Focally [1] 48:6 Followed [1] 29:15 Following [7] 7:15 10:22 18: 21 35:2 43:11 53: 9 60:5 Follows [2] 4:6 16:5 Forensic [3] 26:25 27:3 27: 4 Forget [6] 15:19 19:1 30: 8 33:22 40:6 41:13 Forgot [1] 32:1 Formal [1] 53:8 Forms [4] 44:3 52:5 52: 19 52:22 Forward [1] 6:20 Forwarding [1] 7:5 Four [7] 30:7 33:9 33: 14 51:4 51:4 51:9 51:20	Fourth [2] 22:9 22:11 Frame [3] 33:22 39:3 52: 12 Frames [1] 23:5 Free [1] 46:14 Fresh [8] 19:8 39:20 39: 22 45:20 46:12 46: 13 56:3 56:13 Fresher [1] 45:24 Front [2] 6:1 42:23 Fulfill [1] 24:24 Full [2] 36:14 48:10 Function [2] 29:18 34:10 Furey [4] 2:14 4:16 5: 15 20:14 Furey's [1] 18:22 Furthermore [1] 18:20	44:4 45:3 Grams [2] 29:11 29:11 Granulation [1] 50:11 Greater [3] 28:3 28:3 53: 16 Groedel [41] 2:16 5:13 6: 10 6:18 7:14 8:19 8:23 9:2 9:9 9:16 9:24 10:10 11:18 13:5 13:15 17:18 17:22 17:24 18:24 19:24 21:5 21:22 22:2 22:6 28:17 33:2 36:4 36:22 36:24 38:8 43:2 48:25 49:2 49:13 49:19 56:1 57:16 57:18 58:8 60:5 61:18 Groin [1] 40:3 Gross [1] 47:8 Grossly [1] 19:9 Ground [2] 5:2 39:9 Group [5] 21:11 25:24 26:3 26:5 26:7 Grow [1] 51:19 Growing [1] 51:8 Guess [6] 11:15 14:16 22:3 26:3 39:7 47: 6 Guys [2] 17:9 59:9	[35] 14:25 29:9 29:10 29:22 29:24 31:8 31:10 31:10 31:11 31:12 31:13 31:16 31:18 31:19 31:20 32:4 32:8 32:9 32:14 32:15 32:16 32:17 32:22 32:24 33:19 34:4 34:10 35:20 36:13 37:16 47:17 47:20 48:2 55:14 56:8 Helps [1] 13:7 Hemolyzes [1] 53:1 Hemosiderin [1] 16:14 Hereby [1] 63:4 Herein [2] 1:13 4:2 Hereinafter [1] 4:5 Hereunto [1] 63:17 High [5] 29:12 32:11 32:12 32:14 32:15 Highlighted [1] 34:3 Highly [1] 5:8 Hirschman [1] 59:8 History [1] 37:13 Hold [3] 4:20 24:8 37:: Homicide [1] 27:7 Honest [1] 7:23 Honestly [2] 22:10 23:1 Honor [1] 5:17 Hopefully [1] 4:19 Hooping [1] 42:20 Horrendous [1] 30:1 Horse [1] 58:12 Hospital [15] 7:18 7:22 8: 8 23:23 24:2 24:3
	G		
	Gained [1] 15:17 Gather [5] 4:22 7:21 26: 24 32:25 50:2 General [2] 22:23 23:5 Generality [1] 39:6 Generalized [1] 29:16 Generally [1] 10:15 GEOFFREY [5] 1:12 3:2 4:1 62:25 63:5 Geraldo [1] 55:10 Given [10] 4:23 12:6 12: 15 41:8 49:12 53: 17 53:21 60:20 63: 7 63:11 Gluck [1] 20:18 Graft [4] 29:15 34:14	Half [1] 36:7 Hand [1] 63:17 Handwriting [2] 29:25 35:4 Hate [1] 58:12 Healed [1] 48:21 Health [1] 30:19 Heart	
		H	

GEOFFREY MENDELSON, M.D.

24:11 25:25 26:2 26:6 27:12 28:10 28:13 31:1 44:16 Hospital's [1] 24:5 Hospitals [7] 1:8 14:6 14: 13 24:14 24:15 30: 5 33:1 Hospitals' [1] 33:4 Host [3] 16:6 16:9 48:3 Hour [1] 6:14 Hourly [1] 6:12 Hours [5] 51:17 52:5 52: 15 52:19 52:25 Kouse [1] 28:4 HTD [1] 36:20 Hum [5] 4:10 19:18 25: 22 27:19 42:15 Human [2] 17:8 17:13 Humanly [1] 4:19 Hypercoagulable [1] 43:23 Hypertension [17] 29:2 30:10 30:11 30:12 30:14 30:18 30:24 31:9 31:14 35:22 36:11 44:18 44:23 44:24 45:2 45:8 45:10 lypertensive [1] 32:21 lypotensive [1] 54:25 lypothetically [1] 53:18	[3] 35:8 35:9 35: 24 Implies [3] 34:16 34:17 48:21 Important [2] 21:20 44:15 In-house [1] 28:4 Include [2] 27:5 51:25 Included [1] 15:19 Includes [2] 26:22 27:7 Including [1] 29:5 Incorporated [3] 16:22 50:10 50:13 Increase [1] 44:9 INDEX [1] 3:15 Indicate [6] 5:9 14:4 15: 22 16:24 18:24 37: 12 Indicated [8] 4:14 35:12 38: 5 44:19 46:9 47: 17 53:16 58:9 Indicates [7] 9:19 15:4 17: 24 19:24 48:5 55: 21 61:15 Indicating [5] 7:1 8:20 9:7 17:6 32:11 Indication [1] 50:15 Indicative [1] 14:24 Infarct [14] 32:22 35:20 47:14 47:15 47:22 47:24 48:9 48:12 48:22 48:24 57:8 57:14 57:18 57:24 Infarcted [1] 47:11 Infarction [4] 46:22 46:25 48:19 57:9 Infarctions [3] 29:14 57:1 57: 1 Infarcts	[3] 37:13 53:4 57: 13 Inflammation [1] 43:18 Inflammatory [3] 15:4 16:15 16: 18 Information [13] 5:10 12:6 14: 3 15:25 19:23 37: 9 38:15 38:16 45: 12 47:8 48:15 60: 4 60:8 Ingrowth [1] 51:2 Initial [1] 17:5 Inquire [1] 14:8 Insertion [1] 18:21 Instances [1] 27:6 Institutions [1] 24:23 Insurance [1] 21:3 Insured [2] 21:23 22:4 Integrity [1] 14:12 Intensivist [2] 37:3 37:5 Intention [1] 19:20 Interest [5] 23:11 23:14 23:15 23:17 23:20 Interested [1] 63:15 Internal [2] 34:13 34:14 Interpret [2] 6:2 34:21 Interpretation [3] 14:10 15:17 26:9 Interventions [1] 39:10 Intubation [1] 35:8 Invited [1] 55:10 Involved [4] 25:21 48:10 52:20 56:14 Involvement [1] 18:22	Involving [2] 32:23 41:1 Ischemic [1] 32:22 Issue [1] 7:18 Issued [4] 5:24 10:22 11: 14 22:17 Issues [2] 12:4 13:6 Itself [1] 43:25
J			
			Jacobson [1] 23:7 January [10] 9:2 9:5 9:7 9:16 10:9 10:22 12:3 22:1 33:1 63: 24 Joined [1] 26:6 Judgment [1] 54:9 July [1] 7:8 June [13] 7:14 7:21 7: 24 21:2 25:6 27: 24 27:24 33:24 39: 15 53:18 53:23 54: 17 54:17
K			
			Keep [?] 22:10 22:14 59:15 59:16 59:17 59:21 60:16 Kennedy [1] 59:5 Kink [1] 44:5 Knock [1] 56:16 Knowledge [2] 19:7 31:15 Known [1] 27:10 Kolis [21] 2:4 3:4 4:8 4:11 4:13 4:18 5: 1 5:6 5:13 5:22 12:17 13:3 13:8 36:25 38:10 49:3 60:17 61:2 61:7 61:10 61:15
I			
Idea [2] 28:9 54:4 Identification [1] 12:21 Illness [1] 29:19 Imagine [1] 59:15 Immediately [2] 35:2 51:10 Impending			

GEOFFREY MENDELSON, M.D

L	Length	Lower	Mean
LAD	[1] 16:1	[2] 19:12 28:10	[6] 14:21 17:4 42
[1] 53:12	Less	LPA	16 48:7 49:18 50:
Laid	[2] 18:6 34:17	[1] 2:5	Meaning
[1] 52:10	Letter	Lung	[3] 39:20 45:15
Laminar	[19] 6:25 7:4 8:	[19] 12:13 18:3	58:14
[1] 44:5	23 9:4 9:7 9:16 9	18:18 29:1 30:2	Means
Language	19 10:4 10:11 10:	30:4 30:9 30:13	[7] 34:24 42:11
[1] 34:22	21 10:23 10:25 11:	31:1 31:17 31:21	48:8 48:8 49:24
Large	1 11:11 17:17 17:	32:19 45:14 50:21	49:25 50:9
[21] 6:1 15:3 15:	19 17:22 28:17 33:	50:25 52:2 57:6	Meant
7 15:22 16:1 21:	2	57:12 57:23	[2] 27:23 51:22
11 29:6 29:10 29:	Level	Lungs	Medical
20 32:16 32:16 37:	[1] 53:17	[12] 14:19 14:24	[14] 1:17 11:16
21 37:23 38:21 40:	Likely	15:1 15:2 15:5 30:	11:21 12:25 20:24
24 42:2 46:15 54:	[2] 41:13 41:14	22 36:12 46:2 50:	21:11 22:19 23:24
5 54:7 57:12 60:19	Line	19 51:11 57:1 58:2	28:20 28:23 31:15
Last	[5] 14:16 14:16	Lyse	39:14 44:19 58:5
[6] 27:16 27:22	14:18 15:6 52:1	[1] 52:9	Medical/legal
28:7 32:1 50:15	Lines	M	[4] 6:13 23:7 58:
58:14	[10] 12:16 51:23	M.D.	16 58:19
Late	51:24 52:3 52:4	[4] 3:2 4:1 62:25	Medically
[1] 23:6	52:6 52:8 52:18	63:5	[2] 18:11 40:10
Law	52:24 52:25	Main	Member
[3] 22:12 22:15	Lining	[2] 45:23 45:23	[1] 25:25
23:7	[1] 15:5	Major	Members
Lawful	Listed	[1] 35:22	[1] 22:12
[1] 4:2	[1] 32:7	Malpractice	demory
Lawrence	Litigation	[5] 11:16 11:22	[2] 14:9 22:25
[3] 1:6 4:14 28:22	[1] 11:17	20:24 21:3 21:12	dendelsohn
Lawyers	Lived	Mammary	[9] 1:12 3:2 4:1
[1] 59:1	[1] 41:18	[2] 34:14 34:14	4:8 13:5 18:2 58:
Layer	Located	Man	9 62:25 63:5
[1] 43:25	[1] 37:24	[2] 35:19 58:6	Mendelsohn's
Layman's	Location	Management	[1] 18:20
[1] 15:23	[1] 39:2	[1] 21:15	Mentioned
east	Longstanding	Marc	[1] 29:6
[8] 10:21 12:8 16:	[5] 29:3 29:21 30:	[3] 2:16 17:19 39:	mercifully
3 16:11 17:15 18:	16 31:3 32:6	8	[2] 21:17 21:18
4 18:15 48:22	Look	March	merely
led	[14] 6:4 7:19 10:	[2] 8:19 8:20	[1] 60:9
[1] 16:10	3 10:6 10:6 10:17	dark	mess
lee	11:6 11:23 35:1	[1] 12:19	[1] 4:12
[4] 20:16 33:6 33:	47:4 47:22 58:18	marked	message
3 34:20	58:20 60:2	[3] 3:8 12:21 29:9	[1] 13:15
left	Looked	mask	microscope
[20] 31:11 31:13	[9] 11:13 22:10	[1] 36:23	[1] 51:20
31:19 32:17 32:23	22:16 47:2 48:16	massive	microscopic
34:12 34:14 40:7	48:17 54:20 58:23	[2] 55:23 56:3	[2] 47:8 47:12
41:1 41:5 41:10	59:7	materials	microscopically
41:22 42:10 42:24	Looking	[1] 18:2	[2] 19:11 51:6
43:8 45:21 47:15	[8] 15:13 15:17	math	diddle
48:11 48:12 57:22	15:24 39:20 39:22	[1] 41:20	[1] 61:13
left-sided	54:16 54:21 54:22	matter	light
[5] 31:11 31:13	Looks	[5] 7:22 9:9 9:14	[1] 4:21
31:19 32:17 32:19	[1] 35:3	13:21 31:11	millimeter
left/right	lose	Maynard	[1] 54:14
[1] 42:22	[1] 23:15	[1] 23:8	find

GEOFFREY MENDELSON, M.D

[2] 47:23 59:6	Named	[4] 21:5 36:4 38:8 58:8	7 17:10 21:7 23:14 28:25 34:3 35:18 37:3 41:10 43:16 43:16 43:18 44:7 46:13 49:2 49:3 50:16 52:4 52:24 53:11 53:14 55:12
Minimal	[1] 63:5	Obstruction	3nes
[1] 34:19	Names	[1] 44:7	[1] 46:3
Minimum	[3] 22:15 23:3 23:3	Obtained	Ongoing
[2] 7:24 17:6	3	[1] 28:12	[7] 31:8 42:3 43:16 46:9 52:13 52:16 58:2
Minutes	Nature	Obviously	Opinion
[1] 56:23	[2] 55:22 59:17	[4] 29:16 54:19 57:21 59:18	[44] 8:2 11:7 12:24 15:24 17:14 18:2 18:7 18:8 18:20 19:11 28:18 28:21 29:19 32:3 33:10 35:9 35:14 37:7 38:7 38:12 39:10 39:13 39:16 39:17 39:18 41:9 44:12 45:1 46:1 46:25 47:3 47:3 47:19 47:25 48:12 52:11 54:1 55:12 55:15 55:19 57:13 58:20 58:21 60:9
Misread	Necessitated	Occasionally	Opinions
[1] 55:18	[1] 29:14	[1] 49:6	[7] 4:20 13:6 13:21 13:24 19:25 33:3 58:10
Miss	Necessity	Occasions	Opportunity
[19] 3:4 4:8 4:11 4:18 5:1 5:6 5:13 5:22 12:17 13:3 13:8 36:25 38:10 49:3 60:17 61:2 61:7 61:10 61:15	[1] 8:24	[1] 22:8	[6] 7:9 7:19 8:16 13:23 32:25 55:8
Mitigated	Need	Occluded	Orally
[1] 56:6	[3] 28:17 36:1 47:18	[4] 41:17 43:22 57:11 58:2	[1] 18:24
Mitigates	Needs	Occlusion	Order
[1] 55:13	[1] 37:1	[6] 41:19 41:21 42:17 42:25 44:10 46:11	[1] 38:17
Mixed	Negligence	Offer	ORDERED
[1] 51:25	[1] 22:19	[2] 61:13 63:19	[1] 3:17
Moderate	Never	[2] 19:20 28:18	Ordering
[1] 45:10	[1] 55:8	Offered	[1] 60:23
Moment	New	[1] 59:25	Ordinarily
[1] 35:10	[8] 33:3 39:22 43:24 43:24 45:19 52:9 52:22 52:24	Offering	[2] 11:12 12:7
Momentarily	Next	[2] 13:6 45:1	Organization
[1] 6:4	[3] 15:6 16:5 34:18	Office	[12] 16:16 42:4 43:15 43:17 44:12 50:11 50:23 50:24 51:1 51:10 51:12 51:15
Money	Nice	[1] 63:18	Organized
[1] 6:15	[1] 31:24	Often	[1] 56:13
Months	Night	[1] 56:3	Organizing
[3] 29:4 45:19 48:23	[1] 33:25	Ohio	[18] 15:7 15:22 16:1 29:20 35:22 37:22 37:24 38:22
Morning	Nits	[11] 1:1 1:14 1:16 1:18 2:7 2:19 4:4 63:1 63:4 63:18 63:23	
[8] 33:24 33:25 35:4 35:7 39:15 53:18 53:23 54:17	[1] 17:3	Old	
Most	Notary	[15] 16:8 16:11 17:6 40:2 40:11 40:14 43:12 43:25 45:18 45:18 46:17 47:21 48:9 48:21 56:10	
[5] 29:19 31:16 31:18 50:22 58:18	[3] 1:16 63:3 63:23	Older	
Mount	NOTATION	[1] 18:17	
[4] 1:16 1:17 24:25 25:3	[1] 62:2	Once	
Move	Note	[3] 51:15 52:11 56:14	
[1] 20:22	[6] 8:19 34:2 34:6 34:7 34:25 35:2	One	
Multifactorial	Noted		
[4] 28:25 32:7 35:14 35:15	[1] 53:10		
Mutual	Nothing		
[6] 21:7 21:8 21:14 21:19 21:24 22:5	[3] 28:6 52:21 53:16		
Myocardial	November		
[1] 29:13	[1] 61:4		
	Number		
	[8] 12:10 18:4 18:15 27:20 27:22 28:1 45:17 60:19		
	O		
	02		
Name	[1] 36:20		
[6] 4:9 4:12 6:23 32:1 52:15 59:10	Object		
	[1] 56:1		
	Objection		

GEOFFREY MENDELSON, M.D

40:21 40:24 42:3 46:15 50:20 53:2 54:6 56:15 57:5 57:25 Original [3] 5:25 13:16 19: 23 Origins [1] 46:6 Otherwise [1] 63:15 Outcome [1] 63:16 Outside [1] 43:17 Overall [2] 15:16 37:11 Overlying [1] 46:10 Overseeing [1] 25:16 Own [5] 7:24 24:16 28: 4 47:5 47:23 Oxygen [1] 36:24 Oxygenated [4] 36:12 37:2 37: 4 37:20 Oxygenation [1] 38:23	Participating [1] 6:12 Particular [4] 13:1 15:16 34: 5 55:9 Parts [2] 8:18 34:9 Party [1] 63:15 Past [2] 4:24 23:16 Pathologic [3] 37:17 38:1 38: 18 Pathological [1] 14:10 Pathologically [1] 38:3 Pathologist [8] 5:8 11:5 12: 11 19:6 24:18 31: 24 35:11 42:9 Pathologists [1] 38:1 Pathology [26] 7:17 9:8 22: 19 23:11 23:17 23: 25 24:7 24:19 25: 2 25:8 25:24 26:3 26:5 26:17 26:20 26:21 26:21 26:22 26:22 26:25 27:3 27:4 45:13 54:19 58:24 60:21 Patient [14] 6:1 11:19 23: 3 32:21 37:12 38: 25 43:23 44:8 48: 2 53:22 54:3 56:6 56:7 57:2 Patient's [1] 19:3 Pattern [2] 34:15 44:11 Paul [3] 21:13 21:14 21:19 PE [1] 60:22 Peaks [1] 34:16 Pending [1] 11:16 Percent [12] 25:23 25:23 41:6 41:6 41:11 41:11 41:17 41:21 42:2 42:22 53:11	53:14 Percentage [5] 25:13 25:20 42:25 45:14 45:15 Percentages [1] 41:8 Perfect [1] 44:2 Perfectly [1] 56:18 Perform [8] 24:11 24:13 27:11 27:12 27:14 27:15 27:16 28:11 Performance [1] 26:8 Performed [1] 25:11 Perfuse [2] 57:5 57:23 Perfusion [1] 38:23 Perhaps [1] 30:1 Period [11] 21:8 21:23 22:5 25:8 25:14 41:19 46:19 52:6 52:25 57:24 58:3 Peripheral [1] 43:21 Permit [1] 28:12 Person [2] 36:20 41:10 Personal [1] 7:25 Personally [3] 27:16 47:9 55: 7 Pertains [1] 27:8 PGY [1] 27:23 Phase [1] 51:6 Phone [2] 10:16 11:13 Photographs [1] 49:13 Photomicrographs [1] 49:7 Physical [1] 36:21 Physician [1] 23:3 Physiologic [1] 52:19	Pick [2] 17:3 58:22 Picking [1] 36:1 Picture [2] 37:11 55:21 PIE [3] 21:7 21:19 59 9 Piece [2] 11:16 56:16 Pigment [1] 16:14 Place [3] 38:18 43:16 63:13 Plaintiff [4] 1:6 1:13 2:2 4:2 Plaintiff's [4] 3:8 7:16 12: 19 12:21 PLEAS [1] 1:4 Pleuritis [2] 14:21 15:4 Plural [1] 46:2 PM [1] 34:4 Point [9] 6:14 16:7 21: 12 21:21 25:21 33: 11 33:16 42:0 43: 13 Poor [1] 36:10 Poorly [2] 36:12 37:20 Portion [1] 42:6 Position [3] 23:22 24:8 24: 10 Possibility [2] 42:12 43:11 Possible [7] 4:20 40:10 41: 10 41:14 41:15 56: 3 56:12 Posterior [4] 46:22 47:10 17:15 48:10 Potential [2] 9:4 11:22 Potentially [1] 9:14 Practice
P			
? m. [1] 1:19 Pack [1] 30:8 PAGE [1] 3:3 PAGE/LINE [1] 62:2 Paid [1] 6:21 Paragraph [1] 14:19 Parameters [1] 60:5 Paraphrasing [2] 17:25 41:3 Part [8] 4:12 21:11 23: 3 30:15 30:16 48: 3 48:10 55:18 Partial [1] 44:7 Partially [1] 43:22 Participate [1] 60:10			

GEOFFREY MENDELSON, M.D.

[4] 21:10 21:11 21:15 21:16 Preach [1] 26:11 Preceded [1] 11:13 Preceding [3] 28:1 33:9 33:14 Precipitated [1] 54:8 Precise [2] 17:13 52:15 Precisely [1] 35:5 Predominantly [2] 59:1 59:3 Preliminary [6] 3:10 8:2 9:1 9:20 10:23 14:4 Prepared [2] 17:12 31:5 Presence [1] 63:8 Present [6] 6:11 11:7 18:4 21:2 50:12 50:16 Pressure [7] 29:12 32:11 32:12 32:14 32:15 33:20 54:24 Presumably [2] 19:12 41:18 Preterminally [2] 33:18 33:21 Pretty [1] 23:15 Prevail [1] 21:20 Prevented [1] 18:23 Previously [2] 12:7 43:14 Primary [3] 23:17 26:3 35:16 Prints [1] 49:14 Probability [4] 28:21 30:25 39:14 58:5 Probable [1] 5:8 Procedure [2] 1:15 4:4 Process [5] 35:14 42:3 43:15 46:10 46:19	Processes [1] 38:18 Produced [3] 29:13 44:5 54:23 Program [9] 24:16 24:22 25:2 25:5 25:6 25:9 25:10 28:5 28:6 Progress [1] 35:2 Progressive [1] 44:10 Progressively [2] 44:9 58:1 Promptly [1] 6:21 Pronouncing [1] 4:9 Prosecution [1] 25:18 Prosecutor [1] 31:23 Provide [4] 21:11 51:18 60:4 60:11 Provided [1] 23:6 Public [2] 1:16 63:3 Public/State [1] 63:23 Pull [1] 31:22 Pulmonale [3] 32:2 32:3 32:4 Pulmonary [67] 12:13 15:7 15:20 16:2 16:8 16:17 16:18 16:20 16:21 16:23 16:24 22:20 29:2 29:3 29:6 29:21 29:22 30:9 30:10 30:12 30:14 30:18 30:24 31:9 31:14 35:21 35:23 36:10 37:21 38:6 38:19 38:21 39:5 40:12 40:15 40:22 40:25 41:1 41:22 42:11 42:24 43:20 44:8 44:18 44:22 44:24 45:2 45:5 45:7 45:10 45:18 45:19 45:23 46:2 53:4 53:17 53:22 54:5 55:23 56:3 56:11 56:21	57:1 57:10 57:22 58:1 59:25 Pulmonary-wise [1] 54:5 Pulmonologist [1] 54:10 Pulmonology [2] 53:7 53:8 Pump [1] 36:14 Purpose [4] 1:14 4:3 4:18 11:2 Pursuant [3] 1:14 1:19 4:3 Pursue [1] 59:21 Put [2] 36:23 37:25 Q Qualify [1] 30:4 Quality [2] 14:8 14:12 Quantify [3] 30:3 45:17 54:7 Quantitatively [1] 34:17 Questioning [1] 5:16 Questions [5] 5:4 19:15 39:9 44:14 47:6 Quite [2] 7:23 42:16 Quote [1] 5:14 R Range [2] 18:10 27:4 Rare [1] 52:20 Rate [2] 28:7 28:13 Rather [2] 6:1 54:24 Reabsorbed [1] 50:6 Reach [2] 15:12 47:9 Reached [1] 19:25 Reaching [1] 38:16 Reaction [1] 15:4 Read	[28] 7:9 7:12 8:16 13:3 13:9 13:11 14:18 15:9 18:15 19:2 20:6 20:8 26:16 30:1 32:25 34:7 34:9 34:18 35:4 47:2 48:14 50:14 55:3 55:17 60:25 61:5 61:16 62:21 Reading [4] 26:24 34:2 47:12 61:3 Reads [1] 7:15 Really [8] 4:12 28:25 43:16 43:17 44:15 48:15 51:14 54:6 Reason [1] 55:9 Reasonable [3] 28:20 39:13 58:5 Recannulization [1] 16:12 Receive [2] 11:4 42:21 Received [16] 7:11 8:2 8:5 8:8 8:11 11:1 11:3 11:10 11:17 12:10 12:13 13:15 17:17 17:19 19:24 33:6 Recent [10] 7:15 29:5 29:13 29:14 29:19 29:20 35:20 35:20 37:13 47:14 Recently [4] 13:14 24:21 32:15 33:1 Recognizable [1] 56:20 Recognize [1] 12:12 Recognized [2] 12:11 58:6 Recollection [7] 10:1 12:1 15:20 34:1 41:5 41:7 45:6 Reconstruct [1] 60:18 Reconstructing [1] 59:24 Record
---	---	---	---

GEOFFREY MENDELSON, M.D

<p>[12] 5:17 7:22 7:25 13:9 14:18 15:9 28:23 33:1 33:4 33:6 44:19 54:22</p> <p>Records</p> <p>[10] 7:17 8:8 13:18 18:1 20:1 45:6 54:20 59:16 60:2 60:16</p> <p>Red</p> <p>[2] 52:1 52:8</p> <p>Reduce</p> <p>[1] 18:16</p> <p>Reduced</p> <p>[1] 63:7</p> <p>Reduces</p> <p>[1] 50:11</p> <p>Reference</p> <p>[1] 46:22</p> <p>Referred</p> <p>[1] 27:10</p> <p>Regard</p> <p>[1] 50:9</p> <p>Regarding</p> <p>[2] 5:25 33:2</p> <p>Region</p> <p>[4] 28:14 29:11 40:11 51:9</p> <p>Relate</p> <p>[1] 14:22</p> <p>Related</p> <p>[1] 30:20</p> <p>Relates</p> <p>[1] 15:16</p> <p>Relationship</p> <p>[1] 10:10</p> <p>Relative</p> <p>[2] 9:9 63:14</p> <p>Relatively</p> <p>[1] 28:2</p> <p>Rely</p> <p>[1] 21:18</p> <p>Relying</p> <p>[1] 20:12</p> <p>Remember</p> <p>[3] 5:3 23:1 31:23</p> <p>Remembering</p> <p>[1] 23:2</p> <p>Remind</p> <p>[1] 5:1</p> <p>Reminger</p> <p>[2] 2:17 2:17</p> <p>Remote</p> <p>[9] 29:13 37:12 45:18 46:17 47:15 48:14 48:18 48:21 48:24</p> <p>Remove</p>	<p>[1] 6:7</p> <p>Removed</p> <p>[2] 6:8 6:9</p> <p>Renal</p> <p>[3] 29:17 29:18 43:21</p> <p>Render</p> <p>[2] 39:8 47:18</p> <p>Rendered</p> <p>[2] 23:16 38:7</p> <p>Rendering</p> <p>[3] 39:9 47:3 58:10</p> <p>Reorganization</p> <p>[1] 24:5</p> <p>Repeat</p> <p>[1] 55:16</p> <p>Repeated</p> <p>[1] 43:10</p> <p>Rephrase</p> <p>[1] 17:16</p> <p>Report</p> <p>[29] 3:10 6:8 7:16 8:3 8:4 9:1 11:14 11:23 12:3 12:7 12:15 12:18 12:23 13:17 14:4 17:3 17:5 19:23 20:9 22:17 28:16 29:7 46:21 47:13 49:16 50:15 53:15 60:6 60:10</p> <p>Reporter</p> <p>[2] 12:19 63:22</p> <p>Reports</p> <p>[1] 59:17</p> <p>Represent</p> <p>[3] 4:13 12:12 59:1</p> <p>Representing</p> <p>[1] 5:15</p> <p>Request</p> <p>[1] 5:18</p> <p>Requested</p> <p>[1] 5:24</p> <p>Required</p> <p>[1] 61:17</p> <p>Requirement</p> <p>[1] 61:3</p> <p>Research</p> <p>[1] 4:23</p> <p>Residency</p> <p>[6] 24:16 4:22 25:2 25:9 28:5 28:6</p> <p>Residents</p> <p>[7] 24:16 24:17 24:22 25:10 25:17</p>	<p>26:8 27:18</p> <p>Resolved</p> <p>[6] 49:17 49:19 49:21 49:22 49:24 49:25</p> <p>Resorbed</p> <p>[7] 49:20 50:3 50:4 50:5 50:6 50:9 50:18</p> <p>Respect</p> <p>[1] 58:10</p> <p>Respects</p> <p>[1] 50:7</p> <p>Respiratory</p> <p>[3] 35:8 35:10 35:24</p> <p>Respond</p> <p>[1] 55:13</p> <p>Rest</p> <p>[1] 50:17</p> <p>Result</p> <p>[1] 32:15</p> <p>Resuscitated</p> <p>[2] 55:1 56:6</p> <p>Retained</p> <p>[2] 4:13 4:15</p> <p>Retrace</p> <p>[1] 29:25</p> <p>Return</p> <p>[1] 58:22</p> <p>Review</p> <p>[13] 9:8 10:14 13:20 17:25 24:18 24:19 24:19 25:20 28:24 47:4 54:16 58:4 60:9</p> <p>Reviewed</p> <p>[1] 13:17</p> <p>Reviewing</p> <p>[1] 23:10</p> <p>Ridiculous</p> <p>[1] 56:8</p> <p>Right-sided</p> <p>[8] 31:10 31:12 31:16 31:18 31:20 32:4 32:18 32:18</p> <p>Rivera</p> <p>[1] 55:10</p> <p>Rocket</p> <p>[1] 11:5</p> <p>Role</p> <p>[1] 24:24</p> <p>Room</p> <p>[2] 6:6 36:22</p> <p>Rotational</p> <p>[1] 26:10</p> <p>Rules</p> <p>[3] 1:14 4:4 5:2</p>	<p align="center">S</p> <p>Saddle</p> <p>[6] 38:22 40:25 45:22 46:5 46:10 46:15</p> <p>Saint</p> <p>[4] 2:18 21:12 21:14 21:19</p> <p>Scanlon</p> <p>[1] 59:5</p> <p>Scar</p> <p>[1] 50:17</p> <p>Scientist</p> <p>[1] 11:6</p> <p>Seal</p> <p>[1] 63:18</p> <p>Second</p> <p>[3] 14:1 19:8 19:12</p> <p>Secondary</p> <p>[2] 31:19 35:8</p> <p>Section</p> <p>[1] 53:14</p> <p>Sections</p> <p>[2] 15:6 15:12</p> <p>Seeing</p> <p>[4] 34:5 47:20 52:18 60:18</p> <p>Seeking</p> <p>[1] 5:11</p> <p>Sees</p> <p>[1] 46:13</p> <p>Segment</p> <p>[2] 57:11 57:12</p> <p>Segmental</p> <p>[1] 57:10</p> <p>Semantically</p> <p>[1] 18:15</p> <p>Sending</p> <p>[2] 10:2 11:19</p> <p>Sent</p> <p>[11] 6:10 9:24 10:4 10:11 10:13 12:8 12:9 33:2 53:5 53:13 58:17</p> <p>Sentence</p> <p>[1] 15:13</p> <p>Sentences</p> <p>[1] 16:6</p> <p>Separate</p> <p>[2] 40:21 56:20</p> <p>September</p> <p>[3] 1:18 6:25 61:</p> <p>Sequence</p> <p>[1] 10:24</p> <p>Served</p> <p>[1] 26:13</p> <p>Set</p>
--	--	---	---

GEOFFREY MENDELSON, M.D.

[2] 61:4 63:17	14:5 15:15 15:17	Sometime	Start
Setting	27:21 27:25 52:15	[2] 31:1 51:3	[2] 41:15 52:18
[1] 27:12	Size	Somewhat	Started
Settled	[4] 14:12 32:16	[2] 28:3 28:7	[1] 57:4
[1] 59:20	32:17 39:2	Somewhere	Starts
Seven	Sizeable	[9] 9:18 16:25 18:	[4] 51:3 51:15 53
[2] 61:3 61:16	[1] 57:3	9 18:10 27:25 28:	2 56:15
Several	Slid	14 46:6 51:9 52:4	State
[1] 48:22	[1] 28:7	Soon	[7] 1:1 1:16 5:17
Severe	Slide	[1] 52:2	12:23 15:6 63:1
[6] 29:1 29:8 29:	[6] 14:10 15:14	Sorry	63:4
9 30:2 30:24 45:10	47:23 48:16 48:17	[3] 13:2 33:21 55:	Statement
SHEET	58:20	16	[8] 4:16 13:21 20
[1] 62:1	Slides	Sort	25 21:1 23:8 23:
Show	[46] 9:8 9:20 9:	[9] 43:25 45:22	12 53:9 55:25
[2] 19:5 34:2	20 9:25 10:2 10:6	46:14 50:13 50:15	Stating
Showered	10:7 10:11 10:13	51:1 51:5 51:17	[2] 8:21 44:21
[1] 46:16	10:14 10:17 10:18	51:25	Status
Shown	11:1 11:3 11:4 11:	Sound	[1] 36:21
[2] 40:5 46:7	7 11:8 11:10 11:	[1] 35:25	Stay
Shows	14 11:17 11:19 11:	Source	[1] 7:18
[1] 42:3	23 12:8 12:10 12:	[1] 46:8	Stenotypy
Side	13 14:5 14:8 15:	Spaces	[1] 63:8
[2] 21:15 40:7	15 15:18 15:19 15:	[2] 15:1 15:3	Steve
Sided	24 18:1 19:5 28:	Specific	[1] 59:7
[8] 31:10 31:11	24 45:13 47:2 47:	[5] 23:2 33:12 42:	Still
31:12 31:13 31:16	4 47:5 47:18 47:	13 54:7 54:23	[4] 18:17 28:4 41
31:18 31:19 32:17	20 49:7 49:14 53:	Specifically	11 59:1
Sign	5 53:13 58:22 58:	[9] 10:8 15:21 22:	Studies
[1] 61:5	24	22 33:12 34:5 34:	[4] 42:10 42:13
Signature	Slightly	24 39:6 40:6 54:21	42:14 46:7
[2] 17:20 61:20	[1] 14:19	Specifics	Study
Significant	Slow	[1] 33:18	[5] 34:12 37:23
[7] 29:6 30:10 32:	[1] 44:10	Specified	40:1 40:4 40:5
22 35:22 41:18 45:	Slowly	[1] 63:13	Submission
11 53:10	[1] 33:19	Speculate	[1] 9:20
Significantly	Sludging	[1] 22:3	Submit
[1] 28:15	[1] 43:24	Speed	[2] 6:20 13:23
Signs	Small	[1] 11:11	Submitted
[2] 51:10 51:12	[6] 45:19 46:12	Spent	[1] 14:5
Simply	46:13 51:3 51:19	[1] 26:7	Subpleural
[3] 5:17 10:10 23:	57:12	Spoken	[2] 14:20 15:2
3	Smaller	[1] 55:11	Subpoena
Sinai	[2] 45:24 46:13	Squirrel	[3] 1:19 5:24 5:2
[4] 1:17 1:17 24:	Smoker	[1] 49:6	Subsequent
25 25:3	[1] 30:8	SS	[2] 13:16 43:13
Single	Smoking	[1] 1:1	Subsequently
[1] 52:17	[2] 30:9 30:20	Stable	[1] 63:8
Sit	So-called	[1] 33:10	Subspecialty
[1] 12:2	[1] 27:13	Stack	[2] 26:19 27:3
Site	Soft	[1] 6:2	Sudden
[1] 39:2	[1] 16:19	Staff	[2] 44:24 55:1
Sits	Sold	[1] 24:1	Sufficient
[1] 52:7	[1] 21:10	Standard	[1] 14:9
Sitting	Someone	[4] 2:6 12:25 13:	Suggests
[1] 6:1	[7] 11:6 17:11 21:	6 58:10	[1] 36:13
Six	9 26:7 31:24 36:	Standpoint	Suicide
[8] 12:10 12:15	10 48:5	[2] 37:18 38:25	[1] 27:7

GEOFFREY MENDELSON, M.D

Superimposed [1] 29:21 Supervise [1] 24:14 Supervising [4] 25:15 25:15 25:16 26:8 Supervisor [1] 27:18 Supplied [1] 7:25 Support [1] 21:22 Supports [1] 38:23 Suppose [2] 44:15 50:6 Surface [1] 46:15 Surgeon [3] 11:19 33:7 38:4 Surgery [1] 35:21 Surgical [1] 26:22 Surprised [2] 35:16 58:13 Surrounding [1] 27:9 Survive [1] 42:12 Suspect [1] 5:3 Sworn [2] 4:4 63:6 Systemic [1] 44:9 Systole [1] 34:16	18:17 38:23 42:12 42:16 45:13 50:8 Testified [5] 4:5 22:6 22:12 56:19 59:4 Testify [2] 19:16 63:6 Testimony [23] 4:21 8:24 9:5 12:24 18:5 18:12 18:25 19:20 20:3 20:14 23:16 25:9 36:18 41:21 44:17 47:7 47:14 55:3 55:18 55:19 59:25 63:7 63:11 Therefore [1] 31:13 Thereof [1] 11:22 Thickness [1] 48:10 Third [1] 14:18 Three [2] 51:4 51:7 Threw [1] 39:14 Thrombi [1] 44:9 Thromboembolism [8] 29:4 29:22 30:17 31:4 32:6 36:11 39:1 45:5 Thromboembolus [11] 15:8 15:23 16:2 19:4 29:6 29:21 35:23 37:22 40:24 42:3 54:6 Chrombosis [2] 46:7 46:10 Thrombus [7] 16:12 16:13 16:15 16:16 40:5 46:14 51:25 Chroughout [1] 58:3 Tie [1] 38:2 Ciny [1] 44:4 'issue [2] 16:19 50:11 'issues [1] 50:17 Toby [1] 59:7 Today	[9] 4:18 6:16 7:10 12:2 19:15 19:21 22:18 41:21 61:3 Today's [3] 5:23 7:1 60:24 Together [7] 16:24 35:23 36:9 36:15 37:25 38:2 47:13 Tony [1] 59:11 Toss [1] 59:19 Town [1] 10:17 Toxicology [1] 27:8 Track [3] 22:14 43:16 60:19 Training [3] 35:11 53:7 53:8 Transcribed [i] 63:9 Transcript [3] 60:24 62:21 63:10 Transmural [2] 48:6 48:8 Trauma [1] 56:14 Treatment [1] 39:4 Trial [13] 4:21 8:24 9:5 19:16 19:21 35:16 36:1 49:11 52:14 58:10 60:15 60:15 61:4 Triphasic [1] 34:15 True [3] 28:9 62:22 63:10 Truth [1] 63:6 Try [4] 5:10 42:8 55:17 61:17 TUESDAY [1] 1:18 Turbulence [1] 44:6 Two [23] 15:21 16:8 16:11 16:25 17:6	17:10 17:10 17:15 17:16 17:23 18:6 18:8 18:10 43:12 43:14 45:15 47:6 51:7 57:4 57:14 57:20 57:24 58:14 Type [4] 30:4 38:22 40:25 46:5 U Uh-hum [1] 4:10 Ultimate [3] 32:13 33:15 47:25 Ultimately [1] 52:7 Ultrasound [1] 34:4 Um-hum [4] 19:18 25:22 27:19 42:15 Unable [i] 54:13 Unattached [1] 56:13 Under [4] 25:10 51:20 60:8 63:9 Underlying [1] 30:13 Understood [1] 43:5 Unfortunately [2] 52:20 52:23 University [7] 1:8 14:6 14:13 24:15 30:5 33:1 33:4 Unquote [1] 5:14 Unresponsiveness [1] 55:22 Unstable [1] 33:16 UP [13] 4:12 29:5 38:1 44:4 44:7 47:23 49:10 49:12 50:16 56:10 58:1 58:23 51:10 V VTan [8] 8:12 8:14 20:3 46:21 47:3 47:13 53:15 53:15 Variant [1] 50:6
T Taylor [1] 2:4 Taylor-Kolis [2] 2:4 2:5 Teasing [1] 49:4 Telephone [1] 9:23 Term [9] 21:10 23:15 48:21 49:24 50:1 50:2 50:4 50:4 51:5 Terminal [2] 53:20 54:3 Terms [8] 14:21 15:23			

GEOFFREY MENDELSON, M.D.

Vascular [1] 44:10	[10] 7:5 7:8 7:9 8:2 13:17 17:25	[9] 28:1 28:8 28:
Veins [3] 40:6 46:6 56:10	19:2 20:1 55:3 55:18	13 29:5 30:8 45:
Vena [1] 18:21	Week [2] 17:10 45:15	19 46:20 48:23 58:15
Ventricle [6] 46:23 47:10 47:16 47:22 48:11 48:12	Weeks [21] 16:8 16:11 16:25 17:6 17:10 17:10 17:15 17:16 18:6 18:8 18:11 18:14 43:12 43:14 45:16 48:22 48:23 57:4 57:14 57:20 57:24	Yesterday [2] 13:14 17:17
Ventricles [1] 32:23	Whatsoever [1] 6:7	Young [1] 31:24
Verbal [1] 58:20	Whole [3] 16:6 16:9 48:3	Yourself [1] 7:15
Verbally [1] 5:4	Wide [2] 23:21 27:4	Z
Vessel [12] 42:5 43:18 43:19 43:20 44:5 46:7 50:11 50:14 50:17 51:16 51:17 56:16	Wilson [1] 31:25	Zahn's [9] 51:23 51:24 52:1 52:3 52:4 52: 8 52:18 52:24 53:1
Vessels [4] 41:17 46:13 50:22 51:19	Wise [2] 54:4 54:5	Zones [1] 51:24
Via [1] 11:11	Wish [4] 5:16 17:8 17: 9 17:12	
View [2] 33:11 33:17	Witness [20] 1:13 3:2 4:2 4:10 4:15 4:17 4: 25 5:5 5:12 5:19 9:14 49:5 57:17 61:1 61:6 61:8 61: 12 63:5 63:8 63:17	
Vs [1] 1:7	Word [10] 15:12 25:15 25:15 27:6 30:3 34:18 41:15 48:17 49:17 49:22	
W	Write [2] 12:7 60:10	
Waive [1] 61:2	Writing [3] 13:24 20:9 49: 16	
Waived [2] 61:16 61:20	Written [3] 21:22 23:19 60:6	
Wall [16] 15:8 16:17 16:18 16:23 42:5 43:18 43:19 47:15 48:9 48:10 50:10 50:13 51:2 51:16 51:18 56:16	Wrote [3] 12:3 13:16 30: 1	
Walter [1] 22:16	Y	
Walters [1] 22:16	Year [9] 25:8 25:14 27: 17 27:22 27:23 27: 24 28:14 58:18 58: 25	
Wants [1] 11:6	Years	
Wave [1] 34:15		
Webs [2] 45:18 50:14		
Wecht [3] 7:17 48:25 55: 6		
Wecht's		

GEOFFREY MENDELSON, M.D.

January 14, 1999

Marc W. Groedel, Esq.
Reminger & Reminger
The 113 St. Clair Building
Cleveland, Ohio 44114

RE: Lawrence E. Brown
Your File No. 3761-02-36205-98

Dear Mr. Groedel:

At your request, I have examined *six* slides, #A97-152 from University Hospitals of Cleveland, which you sent me.

The slides include several sections of lung and pulmonary artery, as well as a section of artery, consistent with coronary artery.

The lungs are congested and slightly emphysematous with subpleural emphysematous bullae and fibrinous pleuritis. The sections of pulmonary artery contain a large, organizing thromboembolus that is attached to the wall of the artery. There is early recanalization of the thrombus with fibrosis, focal hemosiderin pigment deposition, and scattered chronic inflammatory cells. In addition, there is a chronic inflammatory infiltrate within the wall of the artery, extending out into periautelial soft tissues. These findings are consistent with a thrombus/embolus at least two weeks old. The section of coronary artery shows occlusive, calcific atherosclerosis.

Please let me know if you have any further questions with regard to this case.

Sincerely,

Geoffrey Mendelson M.D.

Geoffrey Mendelson, M.D.
Director, Department of Pathology and Laboratory Medicine

**PLAINTIFF'S
EXHIBIT**

A 9-28-99

PHS MT. SINAI MEDICAL CENTER

ONE MT. SINAI DRIVE, CLEVELAND, OHIO 44106
PHONE (216)421-4404 FAX (216)421-3964

CURRICULUM VITAE

Name GEOFFREY MENDELSON, M.D.

Social Security No. 214-82-6972

Addresses

Office: Department of Pathology and Laboratory Medicine
Mt. Sinai Medical Center
One Mt. Sinai Drive
Cleveland, Ohio 44106-4198

Telephone (216) 421-4400

Home: 33830 Redbridge Lane
Solon, Ohio 44139
Telephone (216) 498-1873

Personal and Family

Date of Birth: October 30, 1948
Place of Birth: Johannesburg, South Africa (U.S. Citizen)
Marital status: Married
Wife's Name: Linda J.
Children: Kevin R. Year: 1973
Clifford S. 1976

Educational Experience

1966-68 B.S., University of Witwatersrand,
Johannesburg, South Africa

1968-72 M.B., B.Ch., University of Witwatersrand,
School of Medicine
Johannesburg, South Africa

1973-73 Medical Internship, Johannesburg General
Hospital, Johannesburg, South Africa

1974-75 Resident, Laboratory Hematology,
South African Institute of Medical Research
and University of Witwatersrand
School of Medicine
Johannesburg, South Africa

1975-77 Resident. Pathology
The Johns Hopkins Hospital
Baltimore Maryland

Educational Experience (cont.)

- | | |
|---------|--|
| 1977-78 | Fellow, Oncology/Pathology
The Johns Hopkins Hospital
Baltimore, Maryland |
| 1978-79 | Chief Resident, Pathology and Surgical Pathology
The Johns Hopkins Hospital
Baltimore, Maryland |

Professional Appointments

Current (1983 - present):

- | | |
|-------------|--|
| University: | Associate Professor of Pathology
Case Western Reserve University
School of Medicine
Cleveland, Ohio |
| Hospital: | Director
Department of Pathology and Laboratory Medicine
Medical Director, Mt. Sinai Reference Laboratory
PHS Mt. Sinai Health Care System
Cleveland, Ohio |

Past:

- | | |
|-----------|---|
| 1983-1987 | Director, Surgical Pathology
University Hospitals of Cleveland
Cleveland, Ohio |
| 1979-1983 | Assistant Professor of Pathology,
The Johns Hopkins University
School of Medicine and Hospital
Baltimore, Maryland |

Honors & Awards

- | | |
|---------|---|
| 1971 | Jack Baynash Prize, Medicine |
| 1972 | Medical Graduates Association Award for Medicine |
| 1972 | Hoechst Award, Top Graduate in Medicine |
| 1979-82 | Junior Faculty Clinical Fellow, American Cancer Society |

Certificates

1976	Flex Examination
1979	American Board of Pathology (Anatomic Pathology)
1983	Licensed to Practice Medicine, State of Ohio (48943)

Active Membership in Professional Societies

1978	The U.S.-Canadian Academy of Pathology
1979	Maryland Society of Pathologists
1981	The Endocrine Society
1982	The Arthur Purdy Stout Society of Surgical Pathologists
1983	Cleveland Society of Pathologists - President, 1993-94
1985	The American Society of Clinical Pathologists
1989	The College of American Pathologists
1990	The Ohio Society of Pathologists

Editorial Boards. Professional Journals

Cancer
The American Journal of Surgical Pathology
The American Journal of Clinical Pathology
Endocrine Pathology
Modern Pathology

Committee Memberships

1985-87	Committee on Promotions and Tenure, Department of Pathology, Case Western Reserve University
1988-	Medical Executive Committee, Mt. Sinai Medical Center
1988-	Medical Education Committee, Mt. Sinai Medical Center (Chairman)
1988-89	Cancer Task Force, Mt. Sinai Medical Center
1989-1993	Information Steering Committee, Mt. Sinai Medical Center
1990-	Council on Graduate Medical Education, Case Western Reserve University
1990-93	Faculty Council, Case Western Reserve University
1991-	Library Committee, Mt. Sinai Medical Center
1991-93	Executive Council of the Medical Executive Committee. Mt. Sinai Medical Center

- 1993-94 Strategic Task Force, Mt. Sinai Medical Center
- 1994 Chairman, Search Committee for Director of Family Medicine, Mt. Sinai Medical Center
- 1994 Search Committee for Director of Obstetrics & Gynecology, Mt. Sinai Medical Center
- 1994- Contracting Committee, Physician-Hospital Organization (PHO), The Mt. Sinai Medical Center
- 1995- Clinical Quality Improvement Committee, Mt. Sinai Medical Center
- 1996- Physician Management Committee, Mt. Sinai Medical Center

National Committee Memberships

- 1989-95 Council on Graduate Medical Education - Resident Education, The American Society of Clinical Pathologists
- 1991- Chairman, Anatomic Pathology Committee, Residents' In-Service Examination, American Society of Clinical Pathologists
- 1995- Anatomic Pathology Council, Commission on Graduate Medical Education, American Society of Clinical Pathologists
- 1995- National Meetings Activities Committee, American Society of Clinical Pathologists
- 1995-1997 Editor, Anatomic Pathology Check Sample Program (Treatment and Diagnosis), American Society of Clinical Pathologists

Membership on Local Society Committees

- 1990-1995 Executive Committee, The Cleveland Society of Pathologists (Society President, 1994-1995)

Director of National Continuing Medical Education Courses and Programs

1. Diagnostic Problems in Fine Needle Aspiration Cytology and Surgical Pathology of the Thyroid. American Society of Clinical Pathologists, Workshops at annual Spring and Fall Meetings, 1985 - Present.
2. Surgical Pathology and Fine Needle Aspiration Cytology of Thyroid. U.S.- Canadian Academy of Pathology. Course at Annual Meetings, 1986-90.
3. Pathology of the Thyroid Gland. College of American Pathologists, Performance Improvement Program, 1985-86.

4. Pathology of Salivary Glands. College of American Pathologists, Performance Improvement Program, 1986.
5. Medullary Thyroid Carcinoma. Practical Reviews in Pathology, Education Reviews, Inc., 1985.
6. Workshop on Diagnostic Immunohistochemistry. American Society of Clinical Pathologists, 1986-1992.
7. Diagnostic Problems in Endocrine Pathology. Tutorial at the annual Spring and Fall Meetings, American Society of Clinical Pathologists, 1986.
8. Diagnostic Problems in Breast Pathology. Tutorial at the annual Spring and Fall Meetings, American Society of Clinical Pathologists, 1988 - Present.
9. Diagnostic Immunohistochemistry. Workshop at the annual meetings of the National Society of Histotechnology, 1989 - Present.
10. Special Diagnostic Techniques in Surgical Pathology. Workshop at the Annual Meeting of the National Society of Histotechnology, 1991 - Present.

Invited Lectures/Presentations

1. Calcitonin and Histaminase in Medullary Thyroid Carcinoma. Duke University Medical Center, April 1979.
2. Immunoperoxidase Methods in Pathology. College of Physicians and Surgeons, Columbia University, April 1980.
3. The Spectrum of Tumors Associated with the Watery Diarrhea Syndrome. The Philadelphia Pathology Society, September 1980.
4. Papillary Cystic Tumor of the Pancreas. Surgical Pathology Specialty Conference, International Academy of Pathology, Chicago, IL, March 1981.
5. The "Atypical" Thyroid Adenoma. The ~~Sixth~~ Annual Postgraduate Course in Diagnosis and Advances in Surgical Pathology, College of Physicians and Surgeons, Columbia University, NY, October 1982.
6. The Spectrum of Pancreatic Islet Hyperplasia-Neoplasia. The Sixth Annual Postgraduate Course in Diagnosis and Advances in Surgical Pathology, College of Physicians and Surgeons, Columbia University, NY, October 1982.
7. Polypeptide Hormone Tumor Markers. International Symposium on "Hormones and Cancer," Buenos Aires, Argentina, May 9-13, 1983.
8. The Role of Immunocytochemistry in the Study of Tumor Markers. International Symposium on "Hormones and Cancer," Buenos Aires, Argentina. May 9-13, 1983.

Invited Lectures/Presentations (cont.)

9. Ectopic Hormone Production: Biological and Clinical Considerations. International Symposium on "Hormones and Cancer," Buenos Aires, Argentina, May 9-13, 1983.
10. Immunoperoxidase Methods: Applications in Diagnostic Pathology. Maryland Society of Pathologists, Baltimore, MD, January 1983.
11. Medullary Thyroid Carcinoma as a Model for the Study of Tumor Cell Heterogeneity. Department of Pathology, University of Pittsburgh, PA, February 1983.
12. The Immunocytochemistry of Medullary Thyroid Carcinoma - Biological and Clinical Considerations. Armed Forces Institute of Technology, Washington, D.C., May 27, 1983.
13. Ectopic Hormones -- Biological and Clinical Considerations. Department of Pathology, University of Colorado Health Sciences Center, Denver, CO, September 1983.
14. Ectopic Hormone Syndromes -- Pathology and Mechanisms. Cleveland Society of Pathologists, March 1984.
15. Applications of Immunocytochemistry in Endocrine Pathology. Immunocyto-chemistry Workshop, Cleveland, OH, September 1984.
16. Medullary Thyroid Carcinoma - What's Old and What's New? South African Institute for Medical Research and Department of Pathology, University of the Witwatersrand School of Medicine, Johannesburg, South Africa, January 1986.
17. Ectopic Hormone Syndromes. Department of Pathology, Washington University School of Medicine, St. Louis, MO, December 1986.
18. Applications of Immunocytochemistry in Endocrine Pathology. Department of Pathology, Hartford Hospital, Hartford, CT, June 1987.
19. Applications of Immunohistochemistry in Gynecologic Pathology, Symposium on "Cytology and Pathology of Gynecological Cancer," Cleveland, OH, June 1987.
20. Medullary Thyroid Carcinoma. Seminar on Thyroid Pathology, Washington Hospital Center, Washington, D.C., September 1987.
21. Medullary Thyroid Carcinoma - **An** Update. Philadelphia Thyroid Society, Philadelphia, PA, April 1988.
22. Surgical Pathology Slide Seminar. Hospital of the University of Pennsylvania, Philadelphia, PA, April 1988.
23. Surgical Pathology Slide Seminar. Medical College of Pennsylvania, Philadelphia, PA, April 1988.

Invited Lectures/Presentations (cont.)

24. Diagnostic Surgical Pathology and Cytology of Pancreatic Neoplasms. Washington D.C. Society of Pathology, Washington, D.C., April 1989.
25. Stromal Lesions of the Breast. Washington Hospital Center, Washington, D.C., April 1989.
26. The Role of Frozen Section in Thyroid -- **Is** it Indicated? Annual Meeting of the American Society of Clinical Pathologists, Dallas, TX, October 1990.
27. Endocrine Pathology Slide Conference. The Chicago Society of Pathologists, Chicago, IL, May 1992.
28. Breast Cancer -- Pathologic and Biologic Considerations. Northern Ohio Histology Society, Cleveland, OH, October 1992.
29. Applications of Immunohistochemistry in Diagnostic Pathology. Washington Hospital Center, Washington, D.C., September 1992.
30. Intraoperative Evaluation of Thyroid. Michigan Society of Pathologists, Ann Arbor, MI, September 1992.
31. Applications of Immunocytochemistry in Head and Neck Pathology. Michigan Society of Pathologists, **Ann** Arbor, MI, September 1992.
32. Intraoperative Evaluation of Thyroid Nodules. SUNY, Stonybrook, N.Y. June 1993.
33. Pathology of the Pancreas. Seminars in Surgical Pathology. Washington Hospital Center, Washington, D.C., October 1993.
34. Intraoperative Evaluation of Thyroid Lesions. Methodist Hospital, Indianapolis, IN, July 1993.
35. Fine Needle Aspiration of Thyroid. Methodist Hospital, Indianapolis, IN, July 1993.
36. Intraoperative Evaluation of Thyroid Nodules. Cleveland Society of Pathologists, Cleveland, October 1993.
37. The Role of Cytology in the Intraoperative Evaluation of Thyroid Lesions. ? Is there any role for Frozen Section. The Cleveland Society of Pathologists, Cleveland, OH, October 1994.
38. Pathology of the Thyroid Gland. The Ohio Society of Pathologists, Columbus, OH, June 1995.
39. Update on Thyroid Pathology. National Teleconference. The American Society of Clinical Pathologists. October 1996.

Articles Published in Professional Journals

1. Mendelsohn, G., Metz, J., and Green, R. Normal Vitamin B12 Turnover in Subacute Combined Degeneration of the Spinal Cord. *J. Lab. Clin. Invest.* 86: 667-671, 1974.
2. Mendelsohn, G., Green, R., Skikne, B.S., and Scott, W.F. Subacute Combined Degeneration of the Spinal Cord and Air Encephalography. *S. Afr. Med. J.* 49: 1937-1938, 1975.
3. Mendelsohn, G. Multiple Tumors in a Renal Transplant Recipient. *Johns Hopkins Med. J.* 139: 253-256, 1976.
4. Mendelsohn, G., Gomperts, E.D., and Gurwitz, D. Severe Antithrombin III Deficiency in an Infant, Associated ~~with~~ Multiple Arterial and Venous Thromboses. *Thrombosis and Haemostasis* 36: 495-502, 1976.
5. Mendelsohn, G., and Hutchins, G.M. Juxtaposition of Atrial Appendages - Reinterpretation as an Accessory Appendage or Atrial Diverticulum. *Arch. Pathol. Lab. Med.* 101: 490-492, 1977.
6. Mendelsohn, G., and Hutchins, G.M. Primary Pulmonary Hypoplasia: Report of a Case with Polyhydramnios. *Amer. J. Dis. Child.* 131 1220-1223, 1977.
7. Olson, J.L., and Mendelsohn, G. Congenital Cystic Adeno-matoid Malformation of the Lung: An Ultrastructural Study. *Arch. Pathol. Lab. Med.* 102: 248-251, 1978.
8. Mendelsohn, G., Bulkley, B.H., and Hutchins, G.M. Cardio-vascular Manifestations of Pseudoxanthoma Elasticum. *Arch. Pathol. Lab. Med.* 102: 298-302, 1978.
9. Rajfer, J., Mendelsohn, G., Arnheim, J., Jeffs, R.D., and Walsh, P.C. Dysgenetic Male Pseudohermaphroditism. *J. Urol.* 119: 525-528, 1978.
10. Weisburger, W.R. Mendelsohn, G., Eggleston, J.C., and Baylin, S.B. Immunohistochemical Localization of Histaminase (Diamine Oxidase) in Decidual Cells of Human Placenta. *Lab. Invest.* 38: 703-706, 1978.
11. Mendelsohn, G., Eggleston, J.C., Weisburger, W.R., Gann, D.S., and Baylin, S.B. Calcitonin and Histaminase in C-cell Hyperplasia and Medullary Thyroid Carcinoma. A Light Microscopic and Immunohistochemical Study. *Am. J. Pathol.* 92: 35-52, 1978.
12. Mirvis, S.E., Mendelsohn, G., Bulkley, B.H., and Hutchins, G.M. Supraaortic Aortic Stenosis with Parafoveolar Cell (C-Cell) Hyperplasia. *Am. J. Med.* 64: 967-973, 1978.
13. Baylin, S.B., Weisburger, W.R., Eggleston, J.C., Mendelsohn, G., Beaven, M.A., Abeloff, M.D., and Ettinger, D.S. Changing Biochemical Patterns in Small Cell Carcinoma of the Lung. *N. Engl. J. Med.* 299: 105-110, 1978.

Articles Published in Professional Journals (Cont.)

14. Baylin, S.B., Mendelsohn, G. Weisburger, W.R., Gann, **D.S.**, and Eggleston, J.C. Levels of Histaminase and L-dopa Decarboxylase Activity in the Transition from C-cell Hyperplasia to Familial Medullary Thyroid Carcinoma. *Cancer* **44**: 1315-1321, 1979.
15. Mendelsohn, G., and Hutchins, G.M. Infective Endocarditis in the ~~First~~ Decade of Life: **An** Autopsy Study of 33 Cases. *Am. J. Dis. Child.* **133**: 619-622, 1979.
16. Abeloff, M.D., Eggleston, J.C., Mendelsohn, G., Ettinger, D.S., **and** Baylin, S.B. Changes in Morphologic and Biochemical Characteristics of Small Cell Carcinoma of the Lung - A Clinicopathologic Study. *Am. J. Med.* **66**: 757-764, 1979.
17. Trump, D.L., Shoback, D.M., and Mendelsohn, G. **Angio-Immunoblastic** Lymphadenopathy with Dysproteinemia. *Johns Hopkins Med. J.* **144**: 101-106, 1979.
18. Trump, D.L., Mendelsohn, G., and Baylin, S.B. Discordance Between Plasma Calcitonin Content and Tumor Cell Mass in Medullary thyroid Carcinoma. *N. Engl. J. Med.* **301**: 253-255, 1979.
19. Mendelsohn, G., D'Agostino, R., Eggleston, J.C., and Baylin, S.B. The Distribution of Beta-Endorphin Immunoreactivity in the Normal Human Pituitary. *J. Clin. Invest.* **63**: 1297-1301, 1979.
20. Mendelsohn, G., Eggleston, J.C., Olson, J.L., Said, S.I., and Baylin, S.B. Vasoactive Intestinal Peptide (VIP) and Its Relationship to Ganglion Cell Differentiation in Neuroblastic Tumors. *Lab. Invest.* **41**: 144-149, 1979.
21. Hutcheon, D., Nygaard, T., Naidich, D., and Mendelsohn, G. Carcinoid Tumor - Clinical Conference. *Johns Hopkins Med. J.* **145**: 170-175, 1979.
22. Baylin, S.B., Mendelsohn, G., Levine, M.A. Medullary Thyroid Carcinoma in Sipple Syndrome. *Johns Hopkins Med. J.* **145**: 201-205, 1979.
23. Hamilton, S.R., Bussey, H.J.R., Mendelsohn, G., Diamond, M.P., Pavlides, G., Hutcheon, D., Morson, D.M., and Yardley, J.H. Ileal Adenomas After Colectomy in Nine Patients with Adenomatous Polyposis Coli/Gardner's Syndrome. *Gastroenterol.* **77**: 1252-1259, 1979.
24. Mendelsohn, G., Eggleston, J.C., and Mann, R.B. Relationship of Lysozyme (Muramidase) to Histiocytic Differentiation in Malignant Histiocytosis. *Cancer* **45**: 273-279, 1950.
25. Mendelsohn, G., Baylin, S.B., and Eggleston, J.C. Relationship of Metastatic Medullary Thyroid Carcinoma to Calcitonin Content of Pheochromocytomas. *Cancer* **45**: 498-502, 1980.

Articles Published in Professional Journals (Cont.)

26. Ettinger, D.S., Rosenshein, N.B., Parmley, T.H., Mendelsohn, G., **and** Baylin, S.B. Tumor Cell *Origin* of Histaminase Activity in Ascites Fluid from Patients **with** Ovarian Carcinoma. *Cancer* 45: 2568-2575, 1980.
27. Shermeta, D., Mendelsohn, G., and Hailer, A.J. Hyper-insulinemic Hypoglycemia of the Neonate Associated **with** Persistent Fetal Histology and Function of the Pancreas. *Ann. Surg.* 191: 182-186, 1980.
28. Cox, C.E., Van Vickie, J., Froome, L.C., Mendelsohn, G., Baylin, S.B., and Wells, A.A., Jr. Carcinoembryonic Antigen and Calcitonin as Markers of Malignancy in Medullary Thyroid Carcinoma. *Surg. Forum* 30: 120-122, 1979.
29. Mendelsohn, G., Bigner, S.H., Eggleston, J.C., Baylin, S.B., and Wells, S.A. Jr. Anaplastic Variants of Medullary Thyroid Carcinoma - A Light Microscopic and Immunohistochemical Study. *Am. J. Surg. Pathol.* 4: 333-341, 1980.
30. Waish, T.J., Hutchins, G.M., Bulkley, B.H., and Mendelsohn, G. Fungal Infections of the Heart: A Clinical and Pathologic Analysis of 51 Patients at Autopsy. *Am. J. Cardiol.* 45: 357-366, 1980.
- "31. Baylin, S.B., **and** Mendelsohn, G. Ectopic (Inappropriate) Hormone Production by Tumors - Mechanisms Involved **and** the Biological **and** Clinical Implications. *Endocrine Rev.* 1: 45-77, 1980.
32. Miller, K.H., Green, W.R., Stark, W.J., Wells, H.A., and Mendelsohn, G. Immunoprotein Deposition in the Cornea. *Ophthalmol.* 87: 944-950, 1980.
33. Taxy, J.B., Mendelsohn, G., and Gupta, P.K. Carcinoid Tumors of the Rectum: Silver Reactions, Fluorescence, and Serotonin Content of the Cytoplasmic Granules. *Am. J. Clin. Pathol.* 74: 791-795, 1980.
34. Shermeta, D.W., **and** Mendelsohn, G. Hyperinsulin Hypo-glycemia in the Neonate: Therapeutic Choices. *J. Ped. Surg.* 15: 398-399, 1980.
35. Vuitch, M.F., **and** Mendelsohn, G. Relationship of Ectopic ACTH Production to Tumor Differentiation: A Morphologic and Immunohistochemical Study of Prostatic Carcinoma with Cushing's Syndrome. *Cancer* 47: 296-299, 1981.
36. Walsh, T.J., **and** Mendelsohn, G. Invasive Aspergillosis Complicating Cushing's Syndrome. *Arch. Int. Mzd.* 141: 1227-1232, 1981.
37. Kuhajda, F.P., Mendelsohn, G., Taxy, J.B., and Long, D.M. Pleomorphic Xanthoastrocytoma: Report of a Case with Light **and** Electron Microscopy. *Ultrastruct. Pathol.* 2: 25-31. 1981.

Articles Published in Professional Journals (Cont.)

38. Craft, C.F., Mendelsohn, G., Cooper, H.S., and Yardley, J.H. Colonic "Precancer" in Crohn's Disease. *Gastroenterology* **80**: 578-584, 1981.
39. Bigner, S.H., Mendelsohn, G., Wells, S.A., Jr., Cox, E.B., Baylin, S.B., and Eggleston, J.C. Medullary Carcinoma of the Thyroid in the Multiple Endocrine Neoplasia IIA Syndrome. *Am. J. Surg. Pathol.* **5**: 459-472, 1981.
40. Wiley, E.L., Mendelsohn, G., and Eggleston, J.C. Distribution of Carcinoembryonic Antigens and Blood Group Substances in Adenocarcinoma of the Colon. *Lab. Invest.* **44**: 507-513, 1981.
41. Berger, C.L., Goodwin, G., Mendelsohn, G., Eggleston, J.C., Abeloff, M.D., Aisner, S., and Baylin, S.B. Endocrine Related Biochemistry in the Spectrum of Human Lung Carcinoma. *J. Clin. Endocrinol. Metab.* **53**: 422-429, 1981.
42. Wiley, E.L., Murphy, P., Mendelsohn, G., and Eggleston, J.C. Distribution of Blood Group substances in Normal Human Colon: Use of the Unlabeled Antibody Immunoperoxidase Technique to Identify A and B Blood Group Substances. *Am. J. Clin. Pathol.* **76**: 806-809, 1981.
43. Wiley, E.L., Mendelsohn, G., Droller, M.J., and Eggleston, J.C. Immunoperoxidase Detection of Carcinoembryonic Antigen and Blood Group Substances in Papillary Transitional Cell Carcinomas of the Bladder. *J. Urol.* **128**: 276-280, 1982.
44. Lippman, S.M., Mendelsohn, G., Trump, D.L., Wells, S.A., Jr., and Baylin, S.B. The Prognostic and Biologic Significance of Cellular Heterogeneity in Medullary Thyroid Carcinoma: A Study of Calcitonin, L-Dopa Decarboxylase, and Histaminase. *J. Clin. Endocrinol. Metab.* **54**: 233-240, 1982.
45. Bauer, T.W., Mendelsohn, G., Humphrey, R.L., and Mann, R.B. Angioimmunoblastic Lymphadenopathy Progressing to Immunoblastic Lymphoma with Prominent Gastric Involvement: An Immunohistochemical Study of Two Cases. *Cancer* **50**: 2089-2093, 1982.
46. Wells, S.A., Jr., Baylin, S.B., Johnsrude, I.S., Harrington, D.P., Mendelsohn, G., Ontjes, D.A., and Cooper, C.W. Thyroid Venous Catheterization in the Early Diagnosis of Familial Medullary Thyroid Carcinoma. *Am Surg* **196**: 505-511, 1982.
- "47. Baylin, S.B., and Mendelsohn, G. Time Dependent Changes in Human Tumors: Implications for Diagnosis and Clinical Course. *Semin. Oncol.* **9**: 504-512, 1982.
48. Qualman, S.J., Mendelsohn, G., Mann, R.B., and Green, W.R. Intraocular Lymphomas: Natural History Based on a Study of Eight Cases and a Review of Literature. *Cancer* **52**: 878-886, 1983.

Articles Published in Professional Journals (Cont.)

49. Kuhajda, F.P., Offutt, L.E., and Mendelsohn, G. The Distribution of Carcinoembryonic Antigen in Breast Cancer: prognostic and Biological Implications. *Cancer* 52: 878-886, 1983.
- *50. Mendelsohn, G., and Baylin, S.B. Medullary Thyroid Carcinoma. *Laboratory Management* 21: 25-35, 1983.
51. Sanfey, H., Mendelsohn, G., and Cameron, J.L. Solid and papillary Neoplasms of the Pancreas: A Potentially Curable Surgical Lesion. *Ann. Surg.* 197: 272-275, 1983.
52. Kuhajda, F.P., Sun, T.T., and Mendelsohn, G. Polypoid Squamous Carcinoma of the Esophagus: A Case Report with Immunostaining for Keratin. *Am. J. Surg. Pathol.* 7: 495-499, 1983.
53. Goodwin, G., Shaper, J.H., Abeloff, M.D., Mendelsohn, G., and Baylin S.B. Analysis of Cell Surface Proteins Delineates a Differentiation Pathway Linking Endocrine and Non-endocrine Human Lung Cancers. *Proc. Natl. Acad. Sci. (USA)* 80: 380-7-3811, 1983.
54. Qualman, S.J., Gupta, P.K., and Mendelsohn, G. Intra-cellular *E. coli* in Urinary Malakoplakia: A Reservoir of Infection and its Therapeutic Implications. *Am. J. Clin. Pathol.* 81: 35-42, 1984.
55. Epstein, J.I., White, C.W., and Mendelsohn, G. Factor VIII Related Antigen and Glial Fibrillary Acidic Protein in the Differential Diagnosis of Central Nervous System Hemangioblastomas. *Am. J. Clin. Pathol.* 81: 285-292, 1984.
56. Schron, D.S., Gipson, T., and Mendelsohn, G. The Histogenesis of Small Cell Carcinoma of the Prostate: An Immunohistochemical Study. *Cancer* 53: 2478-2480, 1984.
57. Epstein, J.I., and Mendelsohn, G. Squamous Carcinoma of the Foot Arising in Association with Longstanding Verrucous Hyperplasia in a Patient with Congenital Lymphedema. *Cancer* 54: 943-947, 1984.
58. Mendelsohn, G., Wells, S.A., Jr., and Baylin, S.B. Relationship of Tissue Carcinoembryonic Antigen and Calcitonin to Tumor Virulence in Medullary Thyroid Carcinoma: An Immunohistochemical Study in Early, Localized, and Virulent Disseminated Stages of Disease. *Cancer* 54: 657-662, 1984.
59. Kuhajda, F.P., Gipson, T., and Mendelsohn, G. papillary Adenocarcinoma of the Prostate: An Immunohistochemical Study. *Cancer* 54: 1328-1332, 1984.

Articles Published in Professional Journals (Cont.)

60. Kuhajda, F.P., Bohn, H., and Mendelsohn, G. Pregnancy Specific Beta-1-Glycoprotein (SP-I) in Breast Carcinoma: Pathologic and Clinical Considerations. *Cancer* 54: 1392-1396, 1984.
61. Schron, D.S., and Mendelsohn, G. Pancreatic Carcinoma with Duct, Endocrine, and Acinar Differentiation: A Histological, Immunocytochemical and Ultrastructural Study. *Cancer* 54: 1766-1770, 1984.
62. Mendelsohn, G., and Diamond, M.P. Familial Ganglio-neuromatous Polyposis of the Large Bowel. Report of a Family with Associated Juvenile Polyposis. *Am. J. Surg. Pathol.* 8: 515-520, 1984.
63. Berger, C.L., DeBustros, A., Roos, B.A., Leong, S.S., Mendelsohn, G., Gessell, M.S., and Baylin, S.B. Human Medullary Thyroid Carcinoma in Culture Provides a Model Relating Growth Dynamics, Endocrine Cell Differentiation, and Tumor Progression. *J. Clin. Endocrinol. Metab.* 59: 338-343, 1984.
64. Mendelsohn, G. Signet Cell-Stimulating Microfollicular Adenoma of the Thyroid. *Am. J. Surg. Pathol.* 8: 705-708, 1984.
65. Abbuhl, M.F. and Mendelsohn, C. A Simple Technique for the Use of Radioimmunoassay Antisera in Immunohisto-chemical Procedures. *J. Histotechnol.* 9: 17-19, 1986.
66. Aron, D.C., Mendelsohn, G., and Roos, B.A. Elaboration of Nonsomatostatin Peptides Containing the Amino-terminal Portion of Prosomatostatin in a Somatostatin-secreting Human Medullary Thyroid Carcinoma Cell Line. *J. Clin. Endocrinol. Metab.* 62: 1273-1242, 1986.
67. Vogel, H.P. and Mendelsohn, G. Laminin Immunostaining in Hyperplastic, Dysplastic and Neoplastic Lesions of the Endometrium and Uterine Cervix. *Am. J. Obstet. Gynecol.* 69: 794-799, 1987.
68. Martin, S.A., Perez-Reyes, N., and Mendelsohn, G. Angio-invasion in Breast Carcinoma: An Immunohistochemical Study of Factor VIII-Related Antigen. *Cancer* 59: 1918-1922, 1987.
69. Mendelsohn, G., de la Monte, S., Dunn, J.L., and Yardley, J.H. Gastric Carcinoid Tumors, Endocrine Cell Hyper-plasia, and Associated Intestinal Metaplasia. Histologic, Histochemical, and Immunohistochemical Findings. *Cancer* 66: 1022-1031, 1987.
70. Al-Kaisi, N., Abdul-Karim, F., and Mendelsohn, G. Atypical Bronchial Carcinoid with Amyloid Stroma; Another Neuroendocrine Tumor with Amyloid Production. *Arch. Pathol. Lab. Med.* 112: 211-214, 1988.

Articles Published in Professional Journals (Cont.)

71. Ballance, W.A., Mendelsohn, G., Carter, J.R., and Abdul-Karim, F.W.: Osteogenic Sarcoma: Malignant Fibrous Histiocytomatous Variant. *Cancer* 62: 763-771, 1988.
- *72. Mendelsohn, G.: Prognosis of Medullary Thyroid Carcinoma. Invited Commentary. *World J. Surg.*
73. Sawady, J., and Mendelsohn, G.: Extrapaneatic Gastri-noma with pancreatic islet cell hyperplasia. *Arch. Pathol. Lab. Med.* 113: 536-538, 1989.
74. Sawady, J., Mendelsohn, G., Sirota, R.L., and Taxy, J.B.: The Intra-thyroid Hyperfunctioning Parathyroid Gland. *Modem Pathol.* 2: 652-657, 1989.
75. Huss, L.J. and Mendelsohn, G.: Medullary Carcinoma of the Thyroid Gland: An Encapsulated Variant Resembling the Hyalinizing Trabecular (Paraganglioma-like) Adenoma of Thyroid. *Modem Pathol.* 3: 581-585, 1990.
76. Sawady, J., Friedman, M.I., Katzin, W.E., and Mendelsohn, G.: Role of the Transitional Mucosa of the Colon in Differentiating Primary Adenocarcinoma from Carcinomas Metastatic to the Colon. *Am. J. Surg. Pathol.* 15: 136-144, 1991.
77. Mair, S., Lash, R.H., Mendelsohn, G., and Sussman, D.: Intraoperative Surgical Specimen Evaluation: Frozen Section, Cytology or Both ? A Comparative Study of 206 Cases. *Am. J. Clin. Pathol.* 96:8-14, 1991.
- * 78. Mendelsohn, G.: Markers as Prognostic Indicators in Medullary Thyroid Carcinoma. *Am. J. Clin. Pathol.* 95:297-298, 1991.
79. Leeming, R., Jenkins, M., and Mendelsohn, G.: Adenoid Cystic Carcinoma of the Breast. *Arch. Surg.* 127:233-235, 1992.
80. Vasef, M., Katzin, W.E., and Mendelsohn, G.: Castleman's Disease: Report of a Case of Malignant Lymphoma in a Patient with Localized Castleman's Disease. *Am. J. Clin. Pathol.* 98:633-636, 1992.
81. Sawady, J., Katzin, W.E., Mendelsohn, G., and Aron, D.: Somatostatin and Prosomatostatin Localization in Neuroendocrine Tumors of the Ampulla. *Am. J. Clin. Pathol.* 97:411-415, 1992.
82. Rudderman, R.H., Guyuron, B., and Mendelsohn, G.: The fate of fresh and preserved, non-crushed and crushed autogenous cartilage in the rabbit model. *Ann. Plastic Surg.* (in press, 1994).
83. Vasef, M., Abbuhl, M.F., Klein, M.A., and Mendelsohn, G.: Multitissue Blocks for Quality Control in Immunohistochemistry. *The J. Histotechnol.* 18: 127-129, 1995.

Books

1. Mendelsohn, G. *Diagnosis and Pathology of Endocrine Diseases*. J.B. Lippincott Co., 1988.

Book Chapters

1. Mendelsohn, G. Histaminase Immunocytochemistry in Medullary Thyroid Carcinoma and Small Cell Lung Carcinoma. Monograph in *Diagnostic Pathology*, Masson Publishing, New York, 1981, pp. 299-312.
2. Mendelsohn G., and Baylin, S.B. Endocrine Markers of Cancer. *In*: *Cancer Markers: Developmental and Diagnostic Significance*, Vol. 2 (sell, S. and Wahren, B., Eds.). Humana Press, New Jersey, 1982, pp. 321-358.
3. Mendelsohn, G., Baylin, S.B., and Tischler, A.S. Vasoactive Intestinal Polypeptide (VIP) in Neurogenic Tumors and Tumor Cells. *In*: *Advances in Polypeptide Hormone Research*, Vol. 1: Vasoactive Intestinal Peptide (Said, S.I., Ed.). Raven Press, New York, 1981, pp. 479-493.
4. Mendelsohn, G. *The Pathology of Lesions Producing the Watery Diarrhea Syndrome*. *In*: *Progress in Surgical Pathology* (Fenoglio, C.M. and Wolff, M., Eds.). Masson Publishing, New York, 1981, pp. 199-216.
5. Baylin, S.B., and Mendelsohn G. Medullary Thyroid Carcinoma -- A Model for the Study of Human Tumor Progression and Cell Heterogeneity. *In*: *Tumor Cell Heterogeneity* (Owens, A.H., Jr., Baylin, S.B., and Coffey, D.S., Eds.). Academic Press, New York, 1982, pp. 9-27.
6. Berger, C.L., Wells, S.A., Jr., Mendelsohn, G., and Baylin, S.B. The Treatment of Medullary Thyroid Carcinoma. *In*: *Current Endocrinologic Therapy* (Kreiger, D.T. and Bardin, C.W., Eds.). B.C. Decker, New Jersey, 1983, pp. 98-104.
7. Mendelsohn, G., and Baylin, S.B. Ectopic Hormone Production -- Biologic and Clinical Considerations. *In*: *Hormones and Cancer* (Soto, R.J., Sartorio, G.C., and Calandra, R., Eds.). Alan R. Liss, Inc., New York, 1983.
8. Mendelsohn, G. Diagnostic Histochemistry and Immunohistochemistry of the Thyroid, Parathyroid, and Adrenal Glands. *In*: *Application of Histochemistry to Pathologic Diagnosis* (Spicer, S.S., Hennigar, G.R., and Garvin, A.J., Eds.). Marcel Dekker, Inc., New York, 1984.

Book Chapters (cont.)

9. Mendelsohn G., and Baylin, S.B. Time Dependent Changes in Human **Tumors**: Implications for Diagnosis **and** Clinical **Behavior**. In: **Tumors** of Unknown **Origin** and Poorly Differentiated Neoplasms (Fer, **M.F.** Oldham, R.R., and Greco, **F.A.**, Eds.). Grune and Stratton, Florida, 1985.
10. Mendelsohn, G., Suarez, M., Hassan, M.O., Subramanyan, S., and Maksem, J.A. Histopathologic, Immunohistochemical and Ultrastructural Studies of Lung Carcinomas. In: Progress in Surgical Pathology (Fenoglio, C.M., and Wolff, M., **Eds.**). Masson Publishing, New York, 1986.
11. Mendelsohn, G., and Maksem, J.A. Divergent Differentiation in Tumors. Pathology and Biologic Considerations. Pathology Annual 1986, Part I, Vol. **21** (Sommers, S.C., Rosen, P.P., Fechner, R.E., **Eds.**), **pp.** 91-109.
12. Nuñez, C., and Mendelsohn, G. Fine Needle Aspiration Cytology of the Thyroid. Pathology Annual 1987.
13. Mendlesohn, G. Pseudotumors of the Endocrine Glands. In: Pseudotumors (Wick, M.R., **Ed.**) (In Preparation).
14. Mendelsohn, G. Pseudotumors of the Breast. In: Pseudotumors (Wick, M.R., **Ed.**) (In Preparation).

Abstracts

1. Green, R., Mendelsob, G., van Tonder, S., and Metz, J. Vitamin B12 turnover in Humans and Fruit Bats with B12 Deficient Neuropathy. Presented at the 18th Annual Meeting of the American Society of Hematology, Dallas, TX, December, 1975.
2. Mendelsohn, G., and Hutchins, G.M. Juxtaposition of the Atrial Appendages Reinterpreted as Accessory Appendage or **Atrial** Appendages or Atrial Diverticulum. Presented at the 65th Annual Meeting of the International Academy of Pathology, Boston, MA, March, 1976. Lab Invest 36: 326, 1976.
3. Mendelsohn, G., Weisburger, W.R., Bayiin, S.B., and Eggieston, J.C. Calcitonin and Histaminase as Biomarkers in the Differentiation between C-Cell Hyperplasia and Medullary Thyroid Carcinoma. Presented at the 67th Annual Meeting of the International Academy of Pathology, Atlanta, GA, March 6-10, 1978. Lab Invest 38: 375. 1978.
4. Mendelsohn, G., Bulkley, B.W., and Hutchins, G.M. Infective Endocarditis **Old** and **New**: **A** Study of 574 Patients Autopsied over **64** Years. Presented at the 67th Annual Meeting of the International Academy of Pathology, Atlanta, GA, March 6-10, 1978. Lab Invest 38: 357, 1978.

Abstracts (cont.)

5. Walsh, T.J., Hutchins, G.M., Bulkley, B.H., and Mendelsohn, G. Fungal Infections of the ~~Heart~~: Clinical and Pathologic Study of 47 Patients. Presented at the 67th Annual Meeting of ~~the~~ International Academy of Pathology, Atlanta, GA, March 6-10, 1978.
6. Weisburger, W.R., Mendelsohn, G., Baylin, S.B., and Eggleston, J.C. The Presence and Variability of Histaminase in Small Cell Carcinoma of the Lung. Presented at the 67th Annual Meeting of the International Academy of Pathology, Atlanta, GA, March 6-10, 1978. Lab Invest 38: 371, 1978.
7. Baylin, S.B., Weisburger, W.R., Mendelsohn, G., Abeloff, M.D., and Eggleston, J.C. Variable Biochemical Patterns in Small Cell Lung Carcinoma—Biological and Clinical Implications. Presented at the Annual Meeting of the American Association of Cancer Research, Washington, DC, April 7, 1978. Proc Am Assoc Cancer Res 19: 223, 1978.
8. Baylin, S.B., Mendelsohn, G., Weisburger, W.R., Eggleston, J.C., and Gann, D.S. Histaminase Activity as a Marker for Transition of C-Cell Hyperplasia to Medullary Thyroid Carcinoma. Presented at the 60th Annual Meeting of the Endocrine Society, Miami, FL, June 16-18, 1978. Endocrinol 102 (Supp.): 105, 1978.
9. Preissig, S.H., Mendelsohn, G., Eggleston, J.C., Wells, S.A., Jr., Baylin, S.B., and Farrell, R.E. Prognostic Factors of Medullary Thyroid Carcinoma in the Multiple Endocrine Neoplasia II Syndrome. Presented at the 68th Annual Meeting of the International Academy of Pathology, San Francisco, CA, March 5-9, 1979. Lab Invest 40: 278, 1979.
10. Mendelsohn, G., Eggleston, J.C., Olson, J.L., Said, S.I., and Baylin, S.B. Vasoactive Intestinal Peptide (VIP) and Its Relationship to Ganglion Cell Differentiation in Neuroblastic Tumors. Presented at the 68th Annual Meeting of the International Academy of Pathology, San Francisco, CA, March 5-9, 1979. Lab Invest 40: 270, 1979.
11. Mann, R.B., Mendelsohn, G., and Eggleston, J.C. Relationship of Lysozyme (Muramidase) to Histiocytic Differentiation in Malignant Histiocytosis. Presented at the 68th Annual Meeting of the International Academy of Pathology, San Francisco, Ca, March 5-9, 1979. Lab Invest@: 273, 1979.
12. Mendelsohn, G., Preissig, S.H., Eggleston, J.C., Baylin, S.B., and Wells, S.A. Jr. Unusual Morphologic Variants of Medullary Thyroid Carcinoma. Presented at the 68th Annual Meeting of the International Academy of Pathology, San Francisco, CA, March 5-9, 1979. Lab Invest 40: 273, 1979.
13. Mendelsohn, G., D'Agostino, R., Eggleston, J.C., and Baylin, S.B. The Distribution of Beta-endorphin Immunoreactivity in the Normal Human Pituitary Gland. Presented at the 61st Annual Meeting of the Endocrine Society, Anaheim, California, June 11-13, 1979. Endocrinol 103, 1979.

14. Cox, C.E., Van Vickle, J., Froome, L.C., Mendelsohn, G., Baylin, S.B., and Wells, S.A., Jr. Carcinoembryonic Antigen and Calcitonin as Markers of Malignancy in Medullary Thyroid Carcinoma. presented at the **Annual** Meeting of the College of Surgeons, Chicago, IL, October, 1979.
15. Mendelsohn, G., Vuitch, F.M., and Taxy, J.B. Relationship of Ectopic **ACTH** Production to Tumor Differentiation: A Morphologic and Immunohistochemical Study of Prostatic Carcinoma with Cushing's Syndrome. Presented at the 69th Annual Meeting of the International Academy of Pathology, New Orleans, LA, February 25-29, 1980. Lab Invest 42: 135, 1980.
16. Craft, C.F., Mendelsohn, G., Cooper, H.S., Yardley, J.H. Colonic "Pre-cancer" in Crohn's Disease. Presented at the 69th Annual Meeting of the International Academy of Pathology, New Orleans, LA, February 25-29, 1980. Lab Invest 42: 109, 1980.
17. Wiley, E.L., Mendelsohn, G.I., Eggleston, J.C. Immunoperoxidase Localization of Blood Group Antigens and Carcinoembryonic Antigens in Colon Cancer. Presented at the 69th Annual Meeting of the International Academy of Pathology, New Orleans, LA, February 25-29, 1980. Lab Invest 42: 160, 1980.
18. Berger, C.L., Mendelsohn, G., Eggleston, J.C., Abeloff, M.D., Baylin, S.B. Endocrine Biochemistry in the Spectrum of Human Lung Carcinoma. Presented at the 62nd Annual Meeting of the Endocrine Society, Washington, DC, June 1980. Proc Endocr Soc, 62nd Annual Meeting, Abstr. 795, p. 273.
19. Qualman, S.J., Mendelsohn, G., Green, W.R. **Intraocular and** Central Nervous System Malignant Lymphomas: A Histopathologic Study of 10 Cases. Presented at the 70th Annual Meeting of the International Academy of Pathology, Chicago, IL, March 2-6, 1981. Lab Invest 44: 53A, 1981.
20. Mendelsohn, G., Oertel, J.E. Encapsulated Medullary Thyroid Carcinomas: Differentiation from "Atypical" Adenomas by Calcitonin Immunocytochemistry. Presented at the 70th Annual Meeting of the International Academy of Pathology, Chicago, IL, March 2-6, 1981. Lab Invest 44: 43A, 1981.
21. Klacsmann, P.G., Cantrell, B.B., Mendelsohn, G., Manley, P.N., Walsh, P.C., Eggleston, J.C. Immunohistochemical Localization of Prostatic Acid Phosphatase and Carcinoembryonic Antigen in Stage A₂ Carcinoma of the Prostate. Presented at the 70th Annual Meeting of the International Academy of Pathology, Chicago, IL, March 2-6, 1981. Lab Invest 44: 32A, 1981.
22. Wiley, E.L., Mendelsohn, G., Droller, M.J., Eggleston, J.C. Immuno-peroxidase Detection of Carcinoembryonic Antigens and Blood Group Substances in Transitional Cell Carcinomas of the Bladder. Presented at the 70th Annual Meeting of the International Academy of Pathology, Chicago, IL, March 2-6, 1981. Lab Invest 44: 75A, 1981.

Abstracts (cont.)

23. Lipman, S.M., Trump, **D.L.**, Mendelsohn, G., Baylin, S.B. Heterogeneous Calcitonin Immunostaining Predicts Poor Prognosis in Medullary Thyroid Carcinoma. Presented at the Annual Meeting of the American Federation for Clinical Research, San Francisco, CA, May 1981. Clin Res 29: A295, 1981.
24. Qualman, S.J., Gupta, P.K., Mendelsohn, G. Nature of Intracellular Bacteria in Genitourinary Malakoplakia: **An** Immunohistochemical Study. Presented at the 71st Annual Meeting of the International Academy of Pathology, Boston, MA, March, 1981. Lab Invest 46: 66A, 1982.
25. Kuhajda, F.P., Mendelsohn, G. Carcinoembryonic Antigen and Alpha-Lact-albumin in Breast Carcinoma: **An** Immunohistochemical Study. Presented at the 71st Annual Meeting of the International Academy of Pathology, Boston, MA, March, 1981. Lab Invest 46: 46A, 1982.
26. Schron, D.S., Gipson, T., Mendelsohn, G. Small Cell Carcinoma of the Prostate: Histogenetic and Immunohistochemical Considerations. Presented at the 71st Annual Meeting of the International Academy of Pathology, Boston, MA, March, 1981. Lab Invest 46: 74A, 1982.
27. Epstein, J.I., White, C.W., and Mendelsohn, G. Factor VIII and Glial Fibrillary Acidic Protein in the Differential Diagnosis of Central Nervous System hemangioblastomas. Presented at the 72nd Annual Meeting of the International Academy of Pathology, Atlanta, GA, February 27-March 4, 1983. Lab Invest 48: 23A, 1983.
28. Kuhajda, F.P., Bauer, T.W., Moore, G.W., and Mendelsohn, G. Pregnancy-Associated Alpha-2 Glycoprotein Positivity and Extensive Necrosis are Predictors of Early Recurrence in Stage I, Estrogen-Receptor Negative Breast Carcinoma. Presented at the 72nd Annual Meeting of the International Academy of Pathology, Atlanta, GA, February 27-March 4, 1983. Lab Invest 48: 47A, 1983.
29. Mendelsohn, G., Gessell, M., Berger, C.L., and Baylin, S.B. Relationship of Carcinoembryonic Antigen and Calcitonin Immunoreactivity to Tumor Virulence in Medullary Thyroid Carcinoma. Presented at the 73rd Annual Meeting of the International Academy of Pathology, San Francisco, CA, March 10-15, 1984. Lab Invest 50: 39A, 1984.
30. Maksem, J.A., Suarez, M., Subramanyan, S., Hassan, M.O., Mendelsohn, G., Kwak, Y-S. Histopathology. Ultrastructure and Immunohistology of Typical Lung Carcinomas. Presented at the Annual Fall Meeting of the American Society of Clinical Pathology, New Orleans, LA, October 27-November 2, 1984.
31. Mendelsohn, G., de la Monte, S., Dunn, J.L., Yardley, J.H. Gastric Carcinoid Tumors and Associated Intestinal Metaplasia. Presented at the 74th Annual Meeting of the International Academy of Pathology, Toronto, Ont., March 11-15, 1985. Lab Invest 52: 123A, 1985.

Abstracts (cont.)

32. Schaub, C., and Mendelsohn, G. Clear Cell Tumors of the Thyroid Gland. Presented at the annual Fall Meeting of the American Society of Clinical Pathology, Las Vegas, NV, November 1985.
33. Ballance, W., Mendelsohn, G., Makley, J., and Carter, J.R. Malignant Fibrous Histiocytomatous Variant **of** Osteogenic Sarcoma. Presented at the **Annual Fall** Meeting of the American **Society** of Clinical Pathology, Orlando, FL, September 1987.
34. Martin, S., and Mendelsohn, G. Angioinvasion in Breast Carcinoma: **An** Immunohistochemical Study of Factor VIII-Related Antigen. Presented at the 76th Annual Meeting of the International Academy of Pathology, Chicago, IL, March 9-13, 1987.
35. Sawady, I., Friedman, M.I., Katzin, W.E., and Mendelsohn, G.: Role of the Transitional Mucosa of the Colon in Differentiating **Primary** Adenocarcinoma from Carcinomas Metastatic to the Colon. Presented at the Annual Fall Meeting of the American Society of Clinical Pathologists, Dallas, TX, October 1990.
36. Mair, S., Lash, R.H., Mendelsohn, G., and Sussman, D. Intraoperative Surgical Specimen Evaluation -- Frozen Section, Cytology or Both'? Presented at the Annual Fall Meeting of the American Society of Clinical Pathologists, Dallas, TX, October 1990.
37. Friedman, M., Schoenfield, L., Mendelsohn, G., et al. Barrett's Esophagus: Long-Term Follow-Up in the Pediatric Population. Presented at the **Annual Fall Meeting of** the American Society of Clinical Pathologists, New Orleans, LA, October 1991.
38. Mair, S., Lash, R.H., and Mendelsohn, G. Aspiration Cytology of *Primary* Stromal Lesions of the Breast. Presented at the *Annual* Fall Meeting of the American Society of Clinical Pathologists, New Orleans, LA, October 1991.

Continuing Medical Education Publications

1. Unusual Morphologic Variants of Medullary Thyroid Carcinoma. ASCP Check Sample II-41, 1980.
2. Microcystic Adenoma (Glycogen-Rich Cystadenoma) of Pancreas. ASCP Check Sample AP 88-6, 1988.
3. Malignant Mixed Tumor of Thyroid Gland. ASCP Check Sample, TD 88-2, 1988.
4. Ovarian Mucinous Cystic Tumor, Mullerian Type, of Borderline Malignant Potential. ASCP Check Sample, in press, 1991.
5. Frozen Section vs. Cytology in the Intraoperative Evaluation of Thyroid. ASCP Check Sample, in press. 1991.

GEOFFREY MENDELSON, M.D.

January 14, 1999

Marc W. Groedel, Esq.
Reminger & Reminger
The 113 St. Clair Building
Cleveland, Ohio 44114

RE: Lawrence E. Brown
Your File No. 3761-02-36205-98

Dear Mr. Groedel:

At your request, I have examined six slides, #A97-152 from University Hospitals of Cleveland, which you sent me.

The slides include several sections of lung and pulmonary artery, as well as a section of artery, consistent with coronary artery.

The lungs are congested and slightly emphysematous with subpleural emphysematous bullae and fibrinous pleuritis. The sections of pulmonary artery contain a large, organizing thromboembolus that is attached to the wall of the artery. There is early recanalization of the thrombus with fibrosis, focal hemosiderin pigment deposition, and scattered chronic inflammatory cells. In addition, there is a chronic inflammatory infiltrate within the wall of the artery, extending out into perivascular soft tissues. These findings are consistent with a thrombus/embolus at least two weeks old. The section of coronary artery shows occlusive, calcific atherosclerosis.

Please let me know if you have any further questions with regard to this case.

Sincerely,

Geoffrey Mendelson M.D.

Geoffrey Mendelson, M.D.
Director, Department of Pathology and Laboratory Medicine

**PLAINTIFF'S
EXHIBIT**

A 9-28-99

PHS MT. SINAI MEDICAL CENTER

ONE MT. SINAI DRIVE, CLEVELAND, OHIO 44106

PHONE (216) 421-4404 FAX (216) 421-3964

GEOFFREY MENDELSON, M.D.

December 11, 1999

Marc W. Groedel, Esq.
Reminger & Reminger
The 113 St. Clair Building
Cleveland, Ohio 44114

RE: Lawrence Brown
Your File Na 3761-02-36205-98

Dear Mr. Groedel:


I have reviewed the additional slides #A97-152 from University Hospitals of Cleveland, which you sent me in this case. These slides were taken from Mr. Brown's heart at the time of autopsy.

The slides show extensive recent transmural myocardial infarction involving both left and right ventricular walls, with evidence of ongoing myocardial necrosis. Mr. Brown's heart was severely compromised by the myocardial infarct, and the presence of ongoing myocardial necrosis is consistent with progressive ischemia related to Severe coronary artery disease as well as the original pulmonary embolus.

The severity of the myocardial ischemic damage suffered by Mr. Brown, together with evidence of ongoing and progressive myocardial damage, reinforces my previously expressed opinions that Mr. Brown's death was the result of heart failure complicating a number of factors, but primarily severe coronary artery disease and recent pulmonary embolism.

Please do not hesitate to contact me if you have any further questions with regard to this case.

Sincerely,



Geoffrey Mendelsohn, M.D.

PHS MT. SINAI MEDICAL CENTER

ONE MT. SINAI DRIVE, CLEVELAND, OHIO 44106

PHONE (216) 421-4404 FAX (216) 421-3964